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VOORWOORD 
Kanker wordt gekenmerkt door de ongeremde groei van kwaadaardige cellen. 
Het is algemeen aanvaard dat de basis van kanker ligt in de beschadiging van het 
DNA in de eel. Dit bevat aile erfelijke informatie die nodig is voor de ontwikkeling en 
instandhouding van een organisms. Dus oak de informatie voor celdeling en allerlei 
regulatie systemen. Regulatie systemen zijn noodzakelijk om aile funkties die een eel 
behoort uit te oefenen, in goede banen te leiden. Als er in het DNA veranderingen 
optreden door beschadiging, bijvoorbeeld door een virusinfektie, radioaktieve straling, 
of langdurige blootstelling aan toxische stoffen, is het mogelijk dat de eel een kankercel 
wordt. Dat wil zeggen dat deze zich ongeremd gaat vermenigvuldigen en niet meer 
luistert naar signalen van buitenaf om hem in toom te houden. Gebeurt dit met cellen 
van ons afweersysteem, dat verantwoordelijk is voor de bescherming van ons lichaam 
tegen infecties, dan kan zich een leukemie ("bloedkanker") of een maligne lymfoom 
("lymfklierkanker") ontwikkelen. 
Men kan verschillende soorten leukemieen onderscheiden aan de hand van het 
type eel dat erbij betrokken is en de snelheid waarmee de ziekte voortschrijdt. 
Bijvoorbeeld een B-CLL, wat betekent chronische lymfatische leukemie van het B-cel 
type (een eel die antilichamen kan maken) en een T-ALL, dat is een acute lymfatische 
leukemie van het T-cel type (een eel die de B-cel kan helpen en die zelf virus 
ge"infekteerde cellen of kankercellen kan opruimen). Weer een andere soort kanker van 
het immuunsysteem is het multipel myeloom, een kanker van plasmacellen. Deze 
vorm van kanker komt voornamelijk voor bij oudere mensen. 
Plasmacellen zijn de meest uitgerijpte cellen van de B-lymfocyten reeks. Zij zijn 
gespecialiseerd in de produktie van antilichamen. Bij patienten met een vergevorderd 
stadium van het multipel myeloom worden veel plasmacellen (soms wei 90%) 
gevonden in het beenmerg, terwijl er normaal slechts 1-5% plasmacellen in het 
beenmerg voorkomen. Dit veroorzaakt problemen doordat zij de andere beenmergcel-
len verdringen en grate hoeveelheden antilichamen produceren. Tesamen kan dat 
aanleiding geven tot nierstoornissen, bloedarmoede, algehele malaise en infekties. Het 
meest kenmerkende van het multi pel myeloom is de aanwezigheid van een paraprotei-
ne (dit zijn de antilichamen gemaakt door de kwaadaardige plasmacellen) in het bloed 
en het optreden van botafbraak. Dit laatste wordt veroorzaakt door de produktie van 
botafbrekende stoffen door de plasmacellen enjof andere celtypen in het beenmerg. 
Patienten met een multipel myeloom hebben dan oak relatief vaak last van botpijn en 
botbreuk. 
De diagnose multipel myeloom is gemakkelijk te stellen als de ziekte al in een 
vergevorderd stadium is. Men vindt dan een paraprote"ine in het bloed en veel 
plasmacellen in het beenmerg. Bij een multipel myeloom in een vroeg stadium is de 
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diagnose echter moeilijk. Het aantal plasmacellen in het beenmerg is dan slechts in 
geringe mate verhoogd en er is nag geen botafbraak. Er is dan moeilijk onderscheid 
te maken tussen het multipel myeloom en benigne monoclonale gammapathie (BMG), 
wat een goedaardige aandoening is. Deze laatste vorm behoeft niet behandeld te 
worden. 
Mensen met BMG hebben geen klachten en worden eigenlijk bij toeval ontdekt. 
Het kan echter oak zijn dat het een vroeg stadium van een multipel myeloom is, en 
dan is het zaak om zo vroeg mogelijk te behandelen. De vooruitzichten op genezing 
bij een multipel myeloom zijn namelijk zeer slecht als behandeling lang op zich laat 
wachten. Hoe eerder men kan behandelen, hoe beter het is. Echter, de behandeling 
op zichzelf is zwaar. Er wordt vooral behandeld met cytostatica en soms wordt been-
mergtransplantatie toegepast. Het is dus belangrijk om onderscheid te kunnen maken 
tussen BMG en een beginnend multipel myeloom om zo de juiste behandeling te 
kunnen geven. Bovendien is het belangrijk om achter het mechanisme van het 
kankerproces te komen. Aile therapieen zijn tot nag toe gericht op het verwijderen van 
zoveel mogelijk kankercellen en het bestrijden van de symptomen. Als men eenmaal 
de oorzaak kent kan er misschien een therapie gevonden worden die deze oorzaak 
wegneemt zodat preventie en volledige genezing beter mogelijk worden. Dit is echter 
nag toekomstmuziek. 
Het doel van dit onderzoek was om verschillen op te sporen tussen de 
kwaadaardige plasmacellen en normale plasmacellen. Dit is op verschillende niveaus 
onderzocht. Op DNA-niveau werd dit gedaan met behulp van transfectie studies 
waarbij het DNA uit multipel myeloomcellen werd overgebracht in een cellijn. Op deze 
manier is men in staat om oncogenen (genen die kanker kunnen veroorzaken) op te 
sporen. Oak werd het DNA van de tumorcellen onderzocht op de aanwezigheid van 
reeds bekende oncogenen. Op RNA-niveau werd onderzoek gedaan om de expressie 
van oncogenen te bestuderen. De RNA-expressie studies bij multipel myeloom 
patienten zijn echter moeilijk doordat er nogal eens maar een beperkt aantal cellen 
voorhanden is. Bovendien bestaat het celmonster vaak slechts voor een klein deel uit 
tumorcellen. Een gevoelige methode voor RNA-expressie onderzoek is de RNA in situ 
hybridisatie. Met deze techniek is het mogelijk om het RNA in afzonderlijke cellen 
zichtbaar te maken zonder dat de eel kapot gaat, zodat bepaald kan worden in welk 
celtype het betreffende RNA is gevormd. Deze techniek is door ons geschikt gemaakt 
voor RNA-expressie onderzoek van het multipel myeloom. 
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1. INTRODUCTION 
1.1. General features of multiple myeloma 
Multiple myeloma (MM) is the most common manifestation of plasma cell 
malignancy accounting for about 1 per cent of all malignant diseases and slightly more 
than 10 per cent of the hematological malignancies (Blattner, 1980). The incidence of 
MM varies from 1 to 82 per 100.000 in different national and racial groups (Segi, 1977). 
It is predominantly a disease of the elderly. The mean age at diagnosis is around 60 
years (Kyle, 1975). Peak incidence occurs between 75 and 80 years. Only 2 per cent 
of all cases appear in persons below the age of 20 years (Rubenstein, 1949; Howe! 
and Alexanian, 1976). 
The onset of MM is usually insidious and there are often multiple symptoms at 
presentation. Bone pain is the major symptom in about 60 per cent of cases. 
Symptoms of anaemia and uraemia account for perhaps a further 20 per cent, infection 
another 1 0 per cent and the final 10 per cent includes less common presentations 
such as hyperviscosity, amyloidosis, spinal cord compression, acute hypercalcaemia, 
effects of extraosseous tumor and a selection of miscellaneous rarities (Fudenberg and 
Virella, 1980). 
More than 50 per cent of the patients respond to therapy with a more than 75 
per cent reduction in total body myeloma cell mass (Durie and Salmon, 1982). They 
have a rapid improvement in bone pain and reversal of symptoms of hypercalcaemia. 
Bone lesions rarely heal (Rodriguez et al., 1972), depressed levels of normal immuno-
globulins (I g) rarely improve and complete disappearance either of paraprotein or the 
monoclonal plasma cell infiltration of the bone marrow (BM) is unusual. 
Most patients with good initial response remain in clinical "remission" for an 
average of 3 years. Unfortunately, reduction of tumor burden by therapy (generally 
by alkylating agents) rarely exceeds 90 per cent and the large number of residual 
tumor cells leads to eventual relapse in virtually all patients. Such relapses are less 
sensitive to treatment with alkylating agents. The final stages of MM are characterized 
by progressive growth of drug resistant tumor cells, increasing bone pain, hypercal-
caemia, and pathological features. 
A correct diagnosis is not difficult to reach when (1) a monoclonal paraprotein 
is present in serum, urine or both; (2) myeloma cell infiltration is present in the BM; and 
(3) characteristic radiological bone lesions are observed. Diagnostic difficulties arise 
when a paraprotein is detected without the presence of other diagnostic features. 
There is a border region between malignant and benign plasma cell proliferations, 
where it may be impossible to reach an early and correct diagnosis and where only 
the subsequent clinical course can reveal the true nature of the process. Therefore it 
is most important to develop diagnostic tools to discriminate malignant from benign 
monoclonal gammapathies (BMG). Incorrect interpretation may result in an unneces-
sary and even harmful! treatment with cytostatics of patients with BMG or immuno-
deficiency. On the other hand, incorrect interpretation can lead to the discharge of 
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patients with a true B-cell malignancy to whom an appropriate therapy should be given 
(Radl, 1982). Consequently, every patient without typical signs of MM is subjected to 
repeated and expensive control investigations. 
1.2. Cell biological aspects of multiple myeloma 
1.2.1. Myeloma cells 
MM is characterized by a high proportion of plasma cells in the BM and lytic 
bone lesions. The malignant proliferation of plasma cells predominantly takes place in 
the medullary cavity of the axial skeleton. Plasma cell infiltration of other sites is mainly 
a phenomenon seen late in the disease and is not always present (Kapadia, 1980). 
Plasma cells represent the terminal differentiation stage of B-cell development. 
Their main function is antibody production and secretion. The mature plasma cell has 
an eccentric nucleus with a large amount of basophilic cytoplasm, due presumably to 
the abundant RNA required for protein synthesis. Plasma cells are seldomly seen in 
the circulation ( < 0.1% of the lymphocytes) and are normally restricted to the BM and 
the secondary lymphoid organs (e.g. spleen and lymph nodes). In MM the percentage 
of plasma cells in the BM is at least 10% and can even reach values of 90% (Kyle, 
1985). The malignant plasma cell phenotype is moderately heterogeneous among 
different patients. One can distinguish between plasmacytic, lymphoid and plasma-
blastic variants with progressively increasing labeling index and adverse prognosis 
(Greipp and Kyle, 1983; Greipp et al., 1985). The majority of tumor cells are aneuploid 
with a differentiated B-cell phenotype but with subpopulations that also express early 
B (CALLA), possibly T, and even myelomonocytic features (M5, My7) (Durie et al., 
1985, 1989; Epstein et al., 1988; Grogan et al., 1989). 
In vitro culture of myeloma cells is difficult probably due to the low proliferation 
rate of plasma cells (Barlogie et al., 1985). In some cases cell lines could be 
established, mostly from patients in which the disease was already in an advanced 
stage (Latreille et al., 1982; Durie et al., 1985; Katagiri et al., 1985; Gazdar et al., 1986; 
Jernberg et al., 1987). With the outcome of the large scale production of recombinant 
growth factors like interleukins, more and more progress is being made in unraveling 
the requirements for plasma cell growth in vitro (see Section 1.2.3). 
Although the malignant cell type in MM is the plasma cell, the origin of this 
malignancy is considered to take place in a less differentiated precursor cell. B-cells 
have been observed in the peripheral blood, which share the same idiotype as the 
circulating myeloma lg using immunofluorescence studies ( Mellstedt et al., 1974; Van 
Acker et al., 1979; Schedel et al., 1980; Bast et al., 1982; Bagg et al., 1989). By means 
of this idiotypic typing, pre-B cells were traced as the earliest precursor cell-type of MM 
(Kubagawa et al., 1979; Epstein et al., 1988). 
B lymphocytes belonging to the myeloma clone could be detected by Southern 
blot analysis, using probes specific for lg genes (see also Section 1.2.2). With this 
technique it was possible to demonstrate clonal gene rearrangements in peripheral 
blood lymphocytes identical to the gene rearrangements observed in the BM 
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(Berenson et al., 1987; Chiu et al., 1989, Van Riet et al., 1989). However, these findings 
may be due to contamination of the peripheral blood by myeloma cells as stated by 
Shimizu et al. (1980) and Clofent et al. (1989). To date there is no definite answer to 
the question in which differentiation stage of B-cell development the oncogenic event 
takes place. 
1.2.2. Myeloma immunoglobulins 
The most prominent feature of MM is the presence of a so called paraprotein 
or M-component in the serum or urine due to the abnormal production of lg by the 
myeloma cells in the BM. Paraproteins of the lgG isotype are more frequently found 
in MM than those of the lgA, lgD or lgE isotype; in some cases only kappa (x:) or 
lambda ().) light chains can be detected (Radl, 1985). Due to their relatively high 
concentration in serum, paraproteins can be isolated relatively easy. Therefore, much 
of our knowledge about lg is derived from research of myeloma proteins. 
Antibodies produced by a single plasma cell are of one specificity and lg class. 
They are composed of heavy (lgH) and light chains (lgl). Like other cellular proteins, 
lg molecules are synthesized as a result of transcription of specific DNA segments. 
The lgH chains are encoded by chromosome 14, the lgl-x; chains by chromo-
some 2 and the lgL-). chains on chromosome 22 (Croce et al., 1979; Shander et al., 
1980; Erikson et al., 1981). lgH chain genes consist of variable (V), diversity (D), 
joining (J) and constant (C) gene segements. The lgl chain genes consist only of V, 
J and C gene segments. By recombining these gene segments, functional lg genes 
are generated (Rosen et al., 1986; Tonegawa, 1983; Yancopoulos and Alt, 1986). For 
every antibody specificity, this recombination or rearrangement process is unique and 
therefore can serve as a tumor specific marker in B-cell malignancy. By means of the 
Southern blot technique using lg-gene specific probes, it is possible to detect these 
rearrangements in cell samples in which the monoclonal cell population constitutes 
only 1% of the mononuclear cells (reviewed by Griesser et al., 1989). 
In MM, lg gene rearrangements could be detected in proportion to the degree 
of marrow plasmacytosis in most cases (Berenson et al., 1987; Chiu et al., 1989; 
Clofent et al., 1989) indicating the monoclonality of the disease. Although in some 
patients, with sufficient numbers of plasma cells in the bone marrow, this monoclonality 
could not be detected by Southern blot analysis (Humphries and Williams, 1989; K. 
Thielemans, personal communication). lg rearrangement studies can resolve the 
question whether the idiotypically positive B cells found in the peripheral blood of some 
MM patients are indeed cells that belong to the malignant clone or just cells that 
adsorbed the paraprotein. Since purification of B cells from the blood does not usually 
lead to a 100% pure B cell population, plasma cells may still be present, and may 
account for the contradicting results obtained with this technique (Shimizu et al., 1980; 
Berenson et al., 1987; Chiu et al., 1989; Clofent et al., 1989). 
1.2.3. Cytokines and multiple myeloma 
In addition to lg, myeloma cells can produce several cytokines. Many efforts 
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have been undertaken to determine the factor that is responsible for the bone lytic 
lesions which are so characteristic for MM. The first evidence for such a factor came 
from myeloma BM cell cultures. The supernatant of short-term BM cultures was found 
to contain a stimulator of bone resorption that was similar to osteoclast activating 
factor (OAF), a cytokine that was produced by human peripheral leukocytes when 
cultured with antigens or mitogens (Mundy et al., 1974). The observation in BM 
biopsies of osteoclasts at resorptive bone surfaces adjacent to infiltrations of myeloma 
cells supported the conclusion that the increase of osteoclastic bone resorption in MM 
is due to the production of OAF by the myeloma cells (Durie et al., 1981). Recent 
advances in biotechnology made it possible to produce virtually pure cytokines in 
sufficient quantities so that their biologic activity could be investigated. Some of them 
showed bone resorbing activity in vitro, e.g. lymphotoxin (LT, TNF.B), tumor necrosis 
factor (TNFa), interleukin-1 (IL-1) and transforming growth factor .B (TGF.B). OAF 
appeared to be identical to IL-1.8 (Dewhirst et al., 1985). TNF.B or LT and IL-1.8 could 
be detected in myeloma cell cultures (Garrett et al., 1987; Cozzolino et al., 1989; 
Kawano et al., 1989; Lichtenstein et al., 1989). 
Normally, IL-1.8 and TNF.B are not detected in mature B cells. The presence of 
these proteins in the myeloma cells suggests that they play a role in myeloma growth 
and differentiation. Several cytokines that stimulate growth and differentiation of human 
B cells have now been described (Kishimoto, 1987). In general they are termed B-cell 
growth factors (BCGF) and B-cell stimulatory factors (BSF). BCGF are IL-2 (Mingari 
et al., 1984), BCGFI and BCGFII (IL-5) (Kishimoto et al., 1985; Muraguchi et al., 1985) 
and r-interferon (IFN-r) (Romagnani et al., 1986). BSF are IL-4 (BSF-1; Defrance et 
al., 1987) and IL-6 (BSF-2, IFN-.82, HGF) (Hirano et al., 1985;1986). IL-1 and comple-
ment factors are also involved in B cell activation and proliferation (Howard et al., 1983; 
Lipsky et al., 1983; Daha et al., 1984). 
IL-1.8 has many different effects on various cell types. Next to osteo-
clast-activation, it can also activate T-cells (Le and Vitek, 1987), induce B-cell 
proliferation (Freedman et al., 1988), B-cell differentiation (Jelinek and Lipsky, 1987) 
and presumably the stimulation of myeloma cell growth through the induction of IL-6 
(Kawano et al., 1989). On the other hand, Anderson et al. (1989) could neither detect 
proliferation nor lg secretion in purified myeloma cells in response to IL-1a or IL-1.8, 
which was also the case for IL-2 and IL-4. 
IL-5 is produced by the myeloma cell line RPMI 8226 and acts as an autocrine 
growth factor in this cell line (Klein et al., 1987). Some freshly purified populations of 
myeloma cells can also proliferate to IL-5 (Anderson et al., 1989). Whether these 
myeloma cells can produce IL-5 themselves is as yet unclear. 
IL-6 is a potential growth factor for B cell hybridomas, plasmacytomas, 
EBV-transformed B-lymphoblastoid cells and myeloma cells (Poupart et al., 1987; Van 
Damme et al., 1987; Muraguchi et al., 1988; Tosato et al., 1988; Anderson et al., 1989). 
Kawano et al. postulated an autocrine growth pattern for myeloma cells by IL-6 based 
on the observation that cultured purified myeloma cells express IL-6 mRNA, secrete 
IL-6, express receptors for IL-6, and proliferate in a specific manner to exogenous 
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recombinant IL-6 (Asaoku et al., 1988; Kawano et al., 1988). This observation has 
been questioned by Klein et al. (1989) who noted that the IL-6 activity resided entirely 
in the adherent cells of the BM. They therefore favored a paracrine growth mechanism 
(see also Chapter 6). 
Most cytokines produced by myeloma cells induce the production and secretion 
of other cytokines by a variety of different cell types present in the BM. Because of this 
cascade of induction and/or suppression of a large variety of factors, it is not easy to 
investigate which events are primary or secondary results of a particular cytokine. 
Unraveling this cytokine network will be of great importance to clarify the mechanisms 
involved in the abnormal proliferation and maturation of myeloma cells and may 
eventually result in new therapies. 
1.3. Oncogenes 
It is widely accepted that neoplastic development in general results from multiple 
genetic changes. Much effort has been devoted to the identification of genetic 
sequences responsible for the oncogenic event. Our current knowledge about these 
oncogenes is derived from two important discoveries: 
1) acute transforming retroviruses contain specific genes responsible for their 
oncogenicity (Huebner and Todaro, 1969; Martin, 1970), called viral oncogenes 
(v-ane); these genes arose from normal cellular genes (proto-oncogenes), 
apparently picked up by an originally non-transforming virus during the course 
of infection; 
2) gene transfection experiments demonstrated that DNA fragments from different 
human tumor cell lines and fresh tumor tissues were able to transform 
non-neoplastic cells with high efficiency (Cooper et al., 1980; Cooper, 1982; 
Pulciani et al., 1982). 
Some of these transforming genes in DNA transfection assays and v-oncogenes are 
homologous, e.g. transforming gene from human bladder carcinoma and the 
oncogene of Harvey sarcoma virus (H-ras) (Chang et al., 1982). 
Since the initial discovery of oncogenes more then 40 oncogenes have been 
identified and the number is still growing. As a consequence, great progress has been 
made in understanding their normal function in cell growth and differentiation. A 
substantial number of the proteins encoded by proto-oncogenes can be arranged in 
three families: 
1) the protein-tyrosine kinases (Hunter and Cooper, 1985); these enzymes 
represent cell surface receptors like erb-B which codes for the transmembrane 
receptor EGF (Downward et al., 1984) or a signal transducers, for example src, 
which codes for a peripheral membrane protein; 
2) the ras proteins (Ellis et al., 1982), which also represent peripheral membrane 
proteins but their functions are analogous toG proteins (Toda et al., 1985); 
3) diverse nuclear proteins (Bishop, 1985), which may be involved in regulation of 
transcription or regulation of DNA replication; for example the myc product, 
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which is suggested to augment transcription from other genes (Kingston et al., 
1985). 
Alterations in a proto-oncogene can lead to aberrant expression of this gene 
which can disturb the normal growth control machinery of the cell, leading to malignant 
transformation. Activation of these genes can be caused by retroviral insertions, DNA 
deletions or amplifications, point-mutations and/or chromosomal translocations. In the 
process of cancer development, the activation of one proto-oncogene seems not to 
be sufficient. Co-operation among several oncogenes is required to achieve full 
transformation, explaining perhaps the multistep process of carcinogenesis. For 
example, ras and myc have been shown to co-operate in the transformation of certain 
primary cells (Land et al., 1983). Experiments with transgenic mice, which had received 
the c-myc on its own, induced an excessive proliferation of B-lymphoid cells but this 
activity was limited and benign. However, these mice almost all developed malignan-
cies of the B-celllineage after variable latency periods, suggesting that this abnormally 
expanded B-cell population is more susceptible to malignant conversion, generated by 
a secondary event, presumably a genetic accident (Harris et al., 1988; Cory et al., 
1989). 
1.3.1. Oncogenes in B-cell neoplasia 
There are several different biological mechanisms whereby oncogenes are 
deregulated in B-cell neoplasia. In Burkitt's lymphoma, three characteristic transloca-
tions are found, involving the c-myc oncogene and the three lg loci. The most common 
one is the 8;14 translocation (t(8;14)) in which the c-myc gene is translocated from 
chromosome 8 to the lgH locus at chromosome 14 in a head to head orientation 
(Taub et al., 1~82; Adams et al., 1983). In the variant t(2;8) and t(8;22) translocations, 
part of the lgl chain genes (located on the human chromosomes 2 and 22, respective-
ly) is moved to the 3' side of the c-myc gene on chromosome 8 in a head to tail 
orientation (De Ia Chapelle et al., 1983; Erikson et al., 1983). In mouse plasmacytomas, 
a similar recombination between the lgH or lgL genes and c-myc occurs (Klein, 1983). 
An obvious explanation for the involvement of the lg genes in these chromosomal 
abnormalities is that these genes are undergoing chromosomal breakage and rejoining 
in the process of formation of the mature lg gene. Chromosomal translocations 
therefore presumably occur as a result of errors in this natural process (Haluska et al., 
1986). 
Regardless of where the breakpoints occur, the c-myc gene associated with the 
translocation is deregulated and expressed, while the normal c-myc gene is silent in 
almost all cases (Nishikura et al., 1983). Thus, the oncogenic potential of the c-myc 
gene product results from the inappropriate expression of the gene and not from the 
generation of an altered c-myc gene product. Deregulated expression of c-myc may 
be due to cis-activation by different lg-gene elements. The normal lgH chain gene 
enhancer can activate c-myc transcription (Fahrlander et al., 1985; Feo et al., 1986). 
On the other hand, the first exon of c-myc is frequently mutated in Burkitt's lymphoma, 
which may effect transcriptional activation (Cesarman et al., 1987). Activation of c-myc 
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probably can also take place over a long distance, as is obviously the case in variant 
Burkitt's lymphoma in which the breakpoints cluster in a pvt-like region, located about 
300 kb 3' of c-myc (Graham and Adams, 1986; Mengle-Gaw and Rabbitts, 1987). The 
pvt-1 , the major locus of murine plasmacytoma variant translocations, was first cloned 
by Webb et al. (1984). In variant plasmacytomas with t{6;15), the Ck locus (on murine 
chromosome 6) is exchanged with the pvt-1 locus (on chromosome 15), which is 
located at least 85 kb 3' of c-myc (Banerjee et al., 1985; Cory et al., 1985; Graham et 
al., 1985). Pvt-1 is a common site of proviral integration in retrovirally induced murine 
T-lymphomas (Graham et al., 1985) and is equivalent to the mis-1 locus, a common 
proviral integration site in rat T-lymphomas (Villeneuve et al., 1986). 
Alterations within this pvt-region appear to be associated with a deregulation of 
the c-myc gene, suggesting that a putative oncogene is located here which product 
has an effect on c-myc transcription over a long distance (Adams et al., 1986). 
Co-amplification of the pvt-region and c-myc is observed in several human 
tumor cell lines, a colon carcinoma cell line, two small-cell lung carcinoma cell lines, 
a large-cell lung carcinoma cell line (Mengle-Gaw and Rabbits, 1987) and one case of 
acute non-lymphocytic leukemia {Asker et al., 1988), indicating that pvt is involved in 
tumor aetiology in several different cell types. 
Evidence that the pvt-region indeed contains a gene that is actively transcribed, 
was obtained only recently by Shtivelman et al. {1989) for humans and mice and by 
Tsichlis et al. {1989) for rats. In human cell lines, transcripts range in size from 1-11 kb, 
in mouse liver cells the transcripts are 0.5 and 4.8 kb, in mouse osteosarcoma cell 
lines additional 0.6-0.7 kb mRNA were detected and in rat T cell lymphoma a± 10 kb 
mRNA was found (Shtivelman and Bishop, 1989; Shtivelman et al., 1989; Tsichlis et 
al., 1989). The functional role of these transcripts in oncogenesis have yet to be 
elucidated. 
Translocations involving the lgH gene other than the t(8;14) have been reported 
in different subtypes of lymphoma and chronic lymphocytic leukemia (CLL). In patients 
with CLL and diffuse small or large cell lymphoma a t{11 ;14) is often found in which the 
breakpoint on chromosome 11 clusters in a region defined as bc/-1 (Yunis,1983; 
Erikson et al., 1984; Tsujimoto et al., 1984a, 1985a). Follicular cell lymphoma is almost 
invariably associated with a t(14;18) in which the breakpoint on chromosome 18 is 
clustered in a region defined as bcl-2 (Yunis, 1983; Tsujimoto et al., 1984b; Cleary and 
Sklar, 1985a; 1985b). Both translocations are probably the consequence of aberrant 
V-0-J joining events leading to the activation of a putative oncogene at the bc/-1 or 
bc/-2 breakpoint regions. Translocations of bcl-2 sequences from chromosome 18 to 
the JH segment at chromosome 14 causes high steady state levels of bc/-2 mRNA 
(Tsujimoto et al., 1985b). The bc/-2 gene encodes two proteins, Bcl-2a and Bcl-2.8 
(Tsujimoto and Croce, 1986). The Bcl-2a gene product is located at the inner surface 
membrane and has GTP-binding activity just like the H-ras gene product (Haldar et al., 
1989). The translocation results in transcription of mRNA of aberrant sizes but does 
not affect the bc/-2 protein coding sequences (Tsujimoto and Croce, 1986). A bc/-1 
product has not been identified until now. 
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1.3.2. Oncogenes in multiple myeloma 
While advances in chromosomal banding and molecular techniques have 
clarified the role of cellular oncogenes in some B cell lymphomas and leukemias, the 
difficulty in obtaining adequate metaphase chromosomes and the absence of specific 
karyotypic aberrations have hindered similar progress in MM. As the c-myc gene is 
often deregulated in murine plasmacytomas (Fahrlander et al., 1985; Potter, 1986), 
c-myc and other oncogenes implicated in B-celllymphomas and leukemias, have been 
studied also in MM. Elevated myc mRNA expression has been detected in 9 out of 37 
patients with MM but resulted only rarely from DNA rearrangements (two out of 37) 
and was not associated with DNA amplification (Selvanayagam et al., 1988). In one 
case the rearranged DNA was cloned and appeared to be derived entirely from 
chromosome 8, indicating a mechanism of c-myc activation different from that in 
Burkitt's lymphoma. In the other cases the mechanism of c-myc activation was not 
clear. Point-mutations in the first exon of c-myc leading to elevated myc mRNA 
expression as in variant Burkitt's lymphoma (Cesarman et al., 1987) could not be 
detected in these cases. Meltzer et al. (1987), on the other hand, reported mutations 
in the 3' region of the first ex on of c-myc (Pvull and Alul endonuclease sites) in 1 0 out 
of 16 human myeloma samples and cell lines. 
Rearrangement of the c-myc gene was also observed in the plasma cell 
myeloma cell line NCI-H929 as well as in the original tumor material (Gazdar et al., 
1986). A complex translocation, in which only chromosome 8 seemed to be involved, 
had interrupted the third exon of the c-myc gene. As a result, a chimeric mRNA was 
expressed that contained the c-myc coding region but in which the c-myc 3' 
untranslated region had been replaced by sequences introduced by the translocation 
event. This chimeric c-myc mRNA was over seven times more stable than c-myc 
transcripts with intact 3' ends (Hollis et al., 1988). 
A c-myc gene amplification with a concomitantly increased level of expression 
was found in 2 out of 3 cases of plasma cell leukemia but not in 21 cases of MM 
(Si.imegi et al., 1985). 
Most of the handful of available true human plasma cell lines have been initiated 
from malignant effusions (a characteristic feature of the aggressive phase) or from 
circulating leukemic cells (Garewal and Durie, 1982; Durie et al., 1985; Si.imegi et al., 
1985; Gazdar et al., 1986) in which c-myc gene alterations can be found. Since c-myc 
gene alteration is not a common feature of all human myelomas it is suggested that 
altered expression of the c-myc gene, by amplification or rearrangement, contributes 
to the highly malignant nature of plasma cell tumors in the leukemic and aggressive 
phases. Such tumors might be more capable of in vitro proliferation. 
A second transforming gene, N-ras, was identified in the myeloma cell line 
NCI-H929 by transfection experiments (Ernst et al., 1988), suggesting that there is a 
co-operation between c-myc and N-ras which leads to a more aggressive stage as was 
demonstrated in transgenic mice (Sinn et al., 1987). It is possible that the disease 
course is associated with and dependent on the sequential activation of transforming 
genes such as myc and ras, which fits in the multi-step theory of carcinogenesis. 
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Next to a higher c-myc mRNA expression in 25% of MM patients, the H-ras gene 
was also highly expressed in 17 out of 23 cases studied (fsuchiya et al., 1988). High 
levels of H-ras p21 protein were present in aneuploid plasma cells suggesting the 
involvement of the H-ras oncogene in the pathophysiology of MM, which was further 
supported by a shorter survival among patients with high p21 levels. The mechanism 
of the H-ras gene activation in these MM cases is as yet unclear. 
Rearrangements of bc/-2 (commonly involved in follicular lymphoma) have not 
been found in MM, consistent with the rarity oft(14;18) translocations. Bc/-1 rearrange-
ments have been detected in five out of 120 patients but without corresponding mRNA 
elevations (Selvanayagam et al., 1987). 
1.4. A mouse model for multiple myeloma 
The availability of tumor models and tumor derived cell lines has greatly 
increased our current knowledge about the pathological processes that occur in a 
variety of malignancies. Several models of plasma cell malignancies have been 
reported in the literature. Spontaneous plasma cell neoplasia have been observed in 
dogs, mice, rats and monkeys (Lingeman, 1969). But most of them cannot be used 
as experimental model for studies on MM because they occur very infrequently and 
transplantation of the malignant cells into allogeneic recipients of the same species 
leads to rejection. A few currently available inbred strains of mice are particularly prone 
to the development of a plasma cell tumor. 
The BALB/c mouse strain is sensitive to induction of a plasmacytoma by 
intraperitoneal injection of mineral oils (Potter and Boyer, 1962). The primary BALB/c 
plasmacytomas occur in the peritoneal connective tissue and most of them secrete lgA 
immunoglobulins. Cells of these plasmacytomas have not been observed to 
metastasize into the BM. Furthermore, the bone lesions which are characteristic for 
MM, are absent (Kobayashi et al., 1961). Only after intravenous transplantation of the 
BALB/c plasmacytoma cells in a sufficient number, the malignant cells infiltrated the 
BM and led to the development of bone lesions in more than 70% of the recipients 
(Kobayashi et al., 1961). Cytogenetic analysis of these plasmacytomas showed 
nonrandom translocations involving chromosome 15, which bears the c-myc gene. 
Reciprocal translocations occurred between chromosome 15 and chromosome 12, 
and between chromosome 15 and chromosome 6 (Klein, 1983; reviewed by Potter, 
1986). The breakpoints in chromosomes 15, 12 and 6 occurred in c-myc, lgH and 
lgL-11:, respectively. These translocations lead, just as in Burkitt's lymphoma (see 
Section 1.3.1.), to an activation of the c-myc oncogene. This murine plasmacytoma 
model has appeared to be useful to elucidate some oncogenic events that occur also 
in Burkitt's lymphoma, but is a model for a localized plasma cell malignancy rather 
than for MM. 
Aging mice of the inbred C57BL/KalwRij strain frequently develop proliferative 
B-cell disorders (Radl, 1981 ). In addition to the relatively frequently occurring idiopathic 
paraproteinaemia (benign monoclonal gammapathy) some old animals of this strain 
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revealed the presence of MM (Radl et al., 1985). Typical myeloma cells showing a 
monoclonal expansion were found in the BM and the spleen, in contrast with primary 
plasmacytomas which originate and grow only locally without involvement of the BM. 
The skeleton of these MM mice revealed osteoporosis with occasional osteolytic 
lesions. This MM could easily be propagated in vivo by intravenous transfer of BM cells 
into recipients of the same strain. Different MM lines (the 5T lines) maintained the 
properties of the original neoplasia in subsequent transplantation generations. The 
primary 5T MM are comparable to MM in man. They originate spontaneously, their 
localization is mainly in the BM, there is a positive correlation of their incidence with 
age, the most frequently observed isotype of the myeloma protein is lgG and bone 
lesions are present. 
1.5. Introduction to the experimental work 
In this thesis studies were performed at the DNA and RNA level of human and 
mouse MM in order to search for genetic defects, associated with MM. The aim of the 
study was to gain more insight into the molecular aspects that lead to the develop-
ment of MM. 
In order to investigate the presence of activated oncogenes which can lead to 
the transformation of normal cells into malignant myeloma cells, transfection studies 
were performed using DNA from several mouse MM lines (Chapter 2). DNA derived 
from three 5T MM lines was transfected to a mouse fibroblast cell line (NIH/3T3). 
Transfected cells were injected into nude mice, resulting in tumor development. The 
appearance of novel restriction fragments in the H-ras banding pattern in DNA isolated 
from tumors derived from two out of three 5T lines studied, may suggest a pathogenic 
role for H-ras in the MM development but no firm evidence for this suggestion was 
obtained. 
In Chapter 3 the c-myc oncogene was studied in the same mouse model. The 
involvement of this oncogene in other B-cell malignancies in both man and mice made 
it a possible candidate to be also activated in MM. By Southern blot analysis of DNA 
derived from BM cells and ascitic cells of several 5T MM lines, data were obtained 
about possible c-myc rearrangements and/or amplifications. Such structural genetic 
changes may activate oncogenes leading to tumor development. 
In Chapter 4 alterations in c-myc and pvt, two genes that are involved in 
Burkitt's lymphoma, were investigated in human MM BM samples. This was done at 
the DNA and RNA level to see whether any rearrangements, amplifications and/or 
overexpression of these genes could be detected. 
In order to study the expression of particular genes in MM BM cells as an 
indication for activation, we set up an in situ hybridization technique to detect mRNA 
at the single cell level. We combined this technique with immunofluorescence labeling 
of cell surface markers to more precisely detect the cell type in which the mRNA was 
present (Chapter 5). With this technique the expression of two cytokines, IL-6 and 
IL-1,8, was investigated in human MM cells. The rationale for this study was that IL-6 
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was suggested to be an autocrine growth factor for myeloma cells and IL-1P could be 
one of the major factors that is responsible for bone destruction, a characteristic 
feature of MM (Chapter 6). 
In Chapter 7, the General discussion, the results of the experimental work are 
discussed in the context of the literature. 
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SUMMARY 
High molecular weight DNA from fresh bone marrow cells from three different 
multiple myeloma (5T2, 5T7 and 5T14) bearing mice were assayed for the presence 
of transmissible activating transforming genes. This was done by a DNA-mediated 
gene transfer technique using NIH/3T3 cells. After DNA transfer the cells were 
inoculated into nude mice. In all three cases tumors developed within 3 weeks while 
mice injected with control NIH/3T3 DNA transfected NIH/3T3 cells did not develop 
tumors within 4 weeks. Secondary transfection with DNA from these tumors ligated to 
a dominant selective marker in order to distinguish between tumor DNA and NIH/3T3 
DNA, gave also rise to tumor development in nude mice. This dominant marker, 
however, may well be able to transform NIH/3T3 into tumorigenic cells by itself as the 
ligated NIH/3T3 DNA transfected NIH/3T3 cells also gave rise to tumor formation. 
Tumor DNA did not show alterations in banding pattern when hybridized with 
the Ki-ras, N-ras, B-/ym or mas probes. However, a clear alteration was observed in 
the H-ras banding pattern of the DNA from tumors derived from NIH/3T3 cells 
transfected with DNA from 5T7 and 5T14. After a second round of transfection, the 
same H-ras alteration was found in the case of 5T14. Whether this changed H-ras 
fragment is associated with any genetic abnormality in murine multiple myeloma is still 
unclear. 
Monoclonal gammapathies. II. Clinical significance and basic mechanisms. EURAGE (1989). J. Radl and 
B. van Camp (eds). pp. 117-123. 
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INTRODUCTION 
The genetic alterations involved in the neoplastic transformation in multiple 
myeloma (MM) are still unknown. In many tumors the presence of oncogenes has 
been detected by their ability to induce transformation of NIH/3T3 cells (1 ). In the case 
of MM, however, so far transformation could not be established with DNA from fresh 
bone marrow cells, although it did occur with DNA from two established human MM 
cell lines (2). The gene(s) responsible for this transformation has not been identified. 
In recent years spontaneously appearing MM in mice were observed (3). These 
MM are transplantable and resemble the human MM very closely in most respects (4). 
Three of these 5T MM lines were analyzed in the tumorigenicity assay described by 
Blair et al. (5). This assay relies on the ability of transformed NIH/3T3 cells to form 
tumors in nude mice. 
MATERIALS AND METHODS 
Cells and cell culture 
5T2, 5T7 and 5T14 bone marrow cell suspensions were prepared as described 
(6). NIH/3T3 clone 224 cells were cultured in a mixture of Ham's F10jDulbecco's 
modified Eagle's medium supplemented with 4% fetal calf serum (Boehringer, 
Mannheim, FRG) and 4% new born calf serum (Flow, Irvine, Scotland). 
Transfection assay 
High molecular weight (MW) genomic DNA of 5T2, 5T7, 5T14 and NIH /3T3 (200 
JLg), in coprecipitate with plasmid pSV 2 neo (10 JLg) (7) containing the neomycin 
resistance (near) marker, was transfected to 10 dishes with NIH/3T3 (2 x 105 
cells/dish) using a modification of the calcium phosphate precipitation method 
developed by Graham and Van der Eb (8). The precipitate remained on the cells for 
17 hours. Three days after transfection, the culture medium was replaced by similar 
medium containing 300 JLgjml G418 (Gibco, Paisly, Scotland). Four weeks later 
resistant cells were trypsinized, pooled and injected into nude mice as described 
below. In a secondary transfection high MW genomic DNA from tumors originating 
from the primary transform ants was partially digested to approximately 50 kb fragments 
with BamHI and ligated to a modified pMCS-vector (9) containing a near marker and 
a human 'A/u' repetitive sequence (pMCS-A/u) and transfected to NIH/3T3 as 
described above. 
Test for tumorigenicity 
Transfected NIH/3T3 cells were injected subcutaneously (s.c.) in athymic 
BALB/c nude mice (2 x 106 cells/mouse). Tumors appearing at the site of injection (5-
21 days) were characterized by Southern blot hybridization and in vitro culture. 
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DNA analysis 
Isolation of genomic, high MW DNA and plasmid DNA, restriction enzyme 
digestion, ligation, gel electrophoresis and Southern blot hybridization were done 
according to standard procedures as described by Maniatis et al. (10). DNA probes 
were 32P-Iabeled by random priming (11 ). The probes used were the 2.6 kb Hindlll 
fragment of chicken 8-/ym (12), the 580 bp SaljEcoRI fragment of a human N-ras 
eDNA (13), the 1.0 kb Hincll fragment of viral Ki-ras (14), a 0.8 kb and 2.9 kb Sstl 
fragment of a human H-ras (14) oncogene and a 2.75 kb EcoRI fragment of a human 
mos gene (16). 
RESULTS 
High MW genomic DNA from 5T2, 5T7 and 5T14 MM bone marrow cells was 
transfected to NIH/3T3 cells in coprecipitation with plasmid pSV2neo, carrying a near 
gene. Near NIH/3T3 transformants were counted, pooled and scored for tumorigenic 
potential by s.c. injection into nude mice 4 weeks after transfection. Some colonies had 
a characteristically transformed phenotype. The number of near colonies was about 
2000/200 JLg DNA in this transfection round. After 18 days, all mice developed tumors 
at the site of injection. In control experiments in which NIH/3T3 cells were transfected 
with NIH/3T3 DNA and injected into recipient mice, tumors did not appear (Table 1). 
Cell lines were established from the tumors. They all were resistent against neomycin, 
indicating that they originated from the transfected NIH/3T3 cells. 
Table 1. Tumorigenicity assay of murine Multiple Myeloma DNA 
DNA 
5T2 
5T7 
5T14 
NIH/3T3 
T24° 
FIRST FOUNDa 
Tumor appearance 
(days) 
13 
18 
14 
7 
SECOND ROUNDb 
Number of Tumor appearence 
tumorsjnumber of (days) 
mice injected 
2/2 13 
2/2 10 
2/2 21 
0/2 14 
2/2 N.T.d 
Number of 
tumors/number of 
mice injected 
4/4 
4/4 
3/4 
4/4 
N.T. 
a. In the first round NIH/3T3 were exposed to both pSV2neo and DNA from the indicated cell 
lines. 
b. In the second round NIH/3T3 cells were exposed to DNA from the first round tumors ligated 
to pMCS-A/u. The negative control was NIH/3T3 DNA ligated to pMCS-A/u. 
c. T24 is a human bladder carcinoma with an activated H-ras oncogene. 
d. N.T. means not tested. 
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For the second round of transfection, DNA of approximately 50 kb was 
prepared from tumors from the first round of transfection and ligated to pMCS-A/u, 
carrying a near gene. In this cases about 7500 near colonies/200 p.g DNA were 
obtained after transfection. Upon s.c. injection into nude mice, all mice developed 
tumors at the site of injection. In this case, however, in the control group in which 
NIH/3T3 cells were transfected with NIH/3T3 DNA ligated to MCS-A/u, all mice 
developed tumors within 14 days (Table 1). This also occurred in a second indepen-
dent experiment (data not shown). In both cases, the cell lines established from these 
tumors were near. 
To determine whether the oncogenic transformation of NIH /3T3 was due to the 
transfer of activated oncogenes present in the genome of 5T2, 5T7 and 5T14 cells, 
chromosomal DNA of the nude mice tumors of the first and second round of 
transfection and of the original bone marrow cells of 5T2, 5T7 and 5T14 MM bearing 
mice, was digested with several restriction endonucleases, size fractionated by gel 
electrophoresis and after transfer to nitrocellulose hybridized with various 32P-Iabeled 
probes. Transfection usually results in rearrangements around the qeue selected for 
and therefore will yield altered restriction fragments when enzymes are used that 
cleave at a sufficient distance from the transfected oncogene. In this way it is possible 
to discriminate between transferred (mouse) oncogenes and the endogenous copies. 
Hybridization with N-ras, Ki-ras, B-/ym and mas revealed no other fragments than those 
of the endogeneous NIH/3T3 genes. When a probe of the human H-ras gene was 
applied was applied, however, an additional hybridizing fragment of 4.3 kb was 
detected in tumors derived from the 5T7 and 5T14 primary transformants and the 5T14 
a 
2 3 4 5 6 7 8 
kb 
4.3 
1.4 
b 
2 3 4 5 6 7 8 
kb 
I 
I 
--i 2.1 
Figure 1. Presence of a novel fragment hybridizing to a human H-ras probe in tumor DNA derived 
from murine MM transfected NIH/3T3. DNA was digested with EcoRI (a) and BamHI (b). Lane 1, 
NIH/3T3; 2, NIH/3T3 ligated to pMCS-Aiu primary transfectant; 3, 5T7; 4, 5T7 in coprecipitate with 
pSV2neo primary transfectant; 5, 5T7 ligated to pMCS-Aiu secondary transfectant; 6, 5T14; 7, 5T14 in 
coprecipitate with pSV2neo primary transfectant; 8, 5T14 ligated to pMCS-Aiu secondary transfectant. 
5T2 DNA was not analyzed. 
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secondary transformants after digestion with EcoRI. A BamHI digest revealed only an 
additional fragment of 2.1 kb in tumors derived from the 5T14 secondary trans 
formants. The tumor DNA derived from the control NIH/3T3 transformants showed 
only the endogenous H-ras gene (Fig. 1). All tumors contained plasmid sequences 
(data not shown) indicating incorporation of the cotransfected or ligated DNA. 
DISCUSSION 
In the present study, a unique mouse model of MM was investigated for the 
presence of oncogenes capable of transforming NIH/3T3 cells. Using cotransfer and 
tumorigenicity in nude mice, tumors developed in the three 5T MM cases and none in 
the NIH/3T3 control. This strongly suggests that 5T MM DNA contains transforming 
genes. In order to detect this murine transforming fragment in the murine genome of 
NIH/3T3, we ligated the DNA from the tumors derived from primary transformants to 
pMCS-A/u in order to select for neomycine resistance in culture and for the presence 
of pMCS-A/u in the genome. We considered that, when the secondary transformants 
would be tumorigenic, the DNA fragment next to pMCS-A/u had to be of 5T origin and 
should contain the transforming sequences. Partial digestion of the DNA in 50 kb 
pieces, in order to ligate it to pMCS-A/u, was not expected to completely destroy the 
transforming gene as the largest known ras gene is about 40 kb. The tumor develop-
ment, however, in the control experiment in which NIH/3T3 DNA itself was ligated to 
pMCS-A/u made it impossible to conclude that the transforming sequences next to 
pMCS-A/u were of 5T origin. They might also be of NIH/3T3 DNA origin. An 
explanation for the tumorigenicity of the ligated NIH /3T3 may be found in the structure 
of pMCS-A/u. This plasmid contains the SV40 promotor sequence (9). Therefore, 
during BamHI ligation, this promotor is put in the very near vicinity of the adjacent 
DNA fragments. This could lead to the activation of a proto-oncogene by SV40 
promotor insertion. However, other explanations, such as spontaneous mutation of 
NIH/3T3 in culture or activation of a proto-oncogene due to the DNA manipulation 
during the transfection by other mechanisms than SV40 promoter insertion, are also 
possible. 
Southern blot hybridization revealed changes in the H-ras banding pattern in 
the tumor DNA from 5T7 and 5T14 primary transfectants and from the 5T14 secondary 
transfectants. The additional fragments are presumably derived from the 5T DNA as 
the NIH/3T3 derived tumor did not reveal these bands. The new band might have 
been generated in the DNA extraction and manipulation or by excision during the 
transforming process. If restriction sites closely linked to the transferred gene were 
destroyed during the transfection process, DNA prepared from tumors derived from 
transformants would contain novel restriction fragments hybridizing to H-ras. Tumors 
derived from 5T14 secondary transformants showed the same novel H-ras hybridizing 
fragment as the tumors derived from primary transformants, suggesting that the H-
ras gene is responsible for tumor development. This is in agreement with the 
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observation that most of the NIH/3T3 transforming genes are members of the ras 
gene family (17). The possible pathogenic role of H-ras in murine MM, however, is 
unclear and needs further investigations. 
In conclusion, the results from the first round transfection assay show that the 
5T DNA has transforming capacity and that presumably the gene responsible for the 
neoplastic transformation of NIH/3T3 cells is H-ras. Secondary transfection data 
supported these conclusions in the case of 5T14 but not in the case of 5T7. However, 
the 5T7 secondary transfection data could not be interpreted 
because NIH/3T3 DNA ligated to pMCS-A/u was tumorigenic by itself so that the assay 
did not select for an activated H-ras gene. 
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3. THE ST MOUSE MULTIPLE MYELOMA MODEL: ABSENCE OF 
C-MYC ONCOGENE REARRANGEMENT IN EARLY TRANSPLANT GENERATIONS 
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SUMMARY 
Consistent chromosomal translocations involving the c-myc cellular oncogene 
and one of the three immunoglobulin loci are typical for human Burkitt's lymphoma, 
induced mouse plasmacytoma (MPC) and spontaneously arising rat immunocytoma 
(RIC). Another plasma cell malignancy, multiple myeloma (MM), arising spontaneously 
in the aging C57BL/KalwRij mice, was investigated in order to see whether the MM 
cells contain c-myc abnormalities of the MPC or RIC type. Rearrangement of the c-
myc oncogene was found in the bone marrow cells only in 5T2 MM transplantation 
line in a mouse of the 24th generation and in none of the seven other MM of the 5T 
series which were of earlier generations. Since the mouse 5T MM resembles the 
human MM very closely, including the absence of consistent structural c-myc 
oncogene abnormalities, it can serve as a useful experimental model for studies on the 
etiopathogenesis of this disease. 
Br. J. Cancer 61, 276-278, 1990. 
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INTRODUCTION 
Consistent chromosomal translocations involving the c-myc cellular oncogene 
and one of the three immunoglobulin loci have been reported in human Burkitt's 
lymphoma, in induced mouse plasmacytoma (MPC) and in spontaneously arising rat 
immunocytoma (RIC) (rev. by Croce & Nowell, 1985; Potter, 1986; Pear et al., 1986; 
Enrietto, 1987}. Translocation is believed to play an important role in the development 
of these tumors (Klein, 1986}. Multiple myeloma (MM) in man is a neoplasm of B cells 
at a differentiation stage comparable to that of MPC and RIC. However, a rearrange-
ment of the c-myc oncogene was reported only in three cases of MM (Gazdar et al., 
1986; Selvanayagam et al., 1988) and in one case of plasma cell leukemia (Yamada 
et al., 1983}. 
In the recent years, several transplantation lines derived from spontaneously 
arising MM in aging C57BL mice became available in our institute. This mouse MM 
resembles the human disease very closely in several aspects (Radl et al., 1988). It is 
of interest to investigate whether the cells of the experimental 5T MM series contain c-
myc abnormalities of the MPC type or whether they resemble the human MM also in 
this respect. The results of this study show that rearrangement of the c-myc oncogene 
was found in the bone marrow of only one of the 5T MM transplantation lines and was 
possibly due to a late event in the progression of this malignancy. 
MATERIALS AND METHODS 
Male and female C57BL/KalwRij mice from the colony of the Institute for 
Experimental Gerontology in Rijswijk, The Netherlands, were used in this study. 
Detailed information on this inbred strain of mice has been published elsewhere 
(Zurcher et al., 1982; Van Zwieten et al., 1984}. 
5T mouse multiple myeloma 
The different 5T MM originated spontaneously in aging C57BL/Ka- LwRij mice 
(Radl et al., 1988). The individual 5T MM were further propagated by intravenous 
transfer of bone marrow or spleen cells into young recipients of the same strain. An 
attempt was also made to grow the individual 5T MM in an ascitic form by transplan-
ting bone marrow cells into the peritoneal cavity of young recipient mice. In four 
instances this was successful. The main characteristics of the individual 5T MM lines 
pertinent to this study are given in Table I. 
Cell preparations 
Cell suspensions from bone marrow and spleen were prepared as described 
(Croese et al., 1987). The percentage of 5T MM cells in these samples was estimated 
by morphology, cytoplasmic immunoperoxidase staining and by analysis of the cellular 
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Table I. C57BL/KaLwRij mouse 5T multiple myeloma lines of spontaneous origin 
5TMM lsotype Transplantation Growth pattern 
nr generation 
5T2 lgG2a-K; 24 moderately 
(17) progressive 
5T7 lgG2b-K; 7 'smoldering MM' 
5T13 lgG2b-K; 4 moderate 
5T14 lgG1-K; 10 aggressive 
(59) 
5T21 lgD-K; 11 atypical 
5T30 lgG2a-K; 3 aggressive 
(3) 
5T33 lgG2b-K; 5 moderately 
(34) progressive 
5T41 lgG3-K; 1 moderate 
Note: generations of the MM in ascitic form are given between parentheses. 
AI 
I 
I--I = 1 000 bp 
Hd 
I 
c-myc 
r-·---~---, 
Hd Hd Hd 
I I I 
Probe-
1.4 Kb 
Hd 
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Remark 
several sublines 
(also ascitic form) 
different sublines 
(also ascitic form) 
(also ascitic form) 
(also ascitic form) 
5' ->3' 
c-myc 
germ line 
AI 
I 
Figure 1. Molecular map of the murine c-myc gene. Restriction sites: Rl, EcoRI; Hd, Hindi//. The third 
exon probe used is denoted by a black box. 
DNA content. Cytoplasmic examination was performed on cytocentrifuge preparations 
(Hijmans et al., 1965) of the suspensions, using PO-Iabeled antibodies (Nordic 
Immunological Laboratories, Tilburg, The Netherlands) specific for the isotype of the 
given 5T MM immunoglobulin (Table 1). The DNA from bone marrow or spleen cells 
was stained with propidium iodine (PI) according to Taylor (1980). The cellular DNA 
content was analysed by measuring the PI fluorescence intensity by a fluorescence-
activated cell sorter (FACS-11, Becton Dickinson, Mountain View, Ca, U.S.A.). 
Southern blot analysis 
High molecular weight DNA was extracted from 0.5 - 1.0 x 108 bone marrow, 
spleen or ascitic cells by the method of Kunkel et al. (1977). The chromosomal DNA 
was digested with the restriction enzymes Hindlll or EcoRI under conditions 
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recommended by the manufacturer (Gibco-BRL, Breda, The Netherlands). Digested 
DNA was electrophoresed on 0.6 - 0.8 % agarose gels in buffer consisting of 89 mM 
TRIS, 89 mM boric acid and 0,2mM EDTA, pH =8.0 and transferred to Gene Screen 
Plus filters in 0.4N NaOH and 0.6M NaCI (16). Filters were prehybridized for two hours 
at ss·c in a solution of 50 mM Tris/HCI,pH 7.5, 10mM EDTA, 1M NaCI, 1% SDS, 0.1% 
sodium pyrophosphate, 0.2% Ficoll, 0.2% polyvinylpyrrolidone 100 JLg/ml salmon 
sperm DNA and hybridized in the same solution overnight with 25 ng of c-myc probe 
with specific activity of approximately 109 cpmjJLg DNA, a 1.4 kb C/ai-EcoRI fragment 
containing the third exon of the human c-myc gene, which was random-primed 32p 
labeled (Boehringer, Mannheim, FRG). After hybridization, filters were washed to a 
stringency of 0.5 x S.S.C. (1 S.S.C. = 75 mM NaCI,7.5mM sodium citrate, 1% SDS) 
0.1% sodium pyrophosphate at 6s·c, and exposed overnight at -7o·c to Kodak XAR-
5 X-ray films. A schema of the murine c-myc gene and the relevant restriction sites are 
shown in figure 1. 
Sensitivity of the technique and controls 
Bone marrow cells from normal mice and from RPC-20 mouse plasmacytoma 
with a known c-myc rearrangement were used as controls. The detection sensitivity 
limit of the c-myc rearrangement in this technique was determined by admixing isolated 
SP2/0 hybridoma cells to normal bone marrow cells in different proportions and was 
found to be about 3 to 4%. In the different 5T MM preparations, the percentages of 
MM cells varied from 15 to 70% and from 7 to 44% for bone marrow and spleen cells, 
respectively. 
23.7 -
9.46-
6.67-
4.26-
2.25-
1.96-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Figure 2. Autoradiogram of DNA from bone marrow cells digested with Hind II/ (lanes 1 - 7) and EcoRI 
(Janes 8- 14). Lanes 1 and 8: 5T2; lanes 2 and 9: 5T7; lanes 3 and 10: 5T14; lanes 4 and 11: 5T33; 
lanes 5 and 12: 5T41; lanes 6 and 13: RPC-20; lanes 7 and 14: normal bone marrow cells. Analyses of 
MM 5T13, 5T21 and 5T30 are not shown. For details see the text. 
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RESULTS 
No rearrangement of the c-myc oncogene was found in any of the individual 5T 
MM (Table I) when spleen cells were investigated. Similar results were obtained when 
bone marrow cells were analysed, however, with one exception. The mouse 5T7, 5T13, 
5T14, 5T21, 5T30, 5T33 and 5T41 MM showed only the germ line fragments of 4.6 kb 
(Hindlll) and 22 kb (EcoRI) as in normal mouse bone marrow (Fig. 2). However, the 
5T2 MM showed an additional hybridizing fragment of 5.4 kb (Hindlll) and 15 kb 
(EcoRI). The same pattern was observed when DNA from 5T2 MM cells originating 
from an animal with an ascitic form of 5T2 MM was investigated (Fig. 3). This indicates 
that the c-myc rearrangement took place in the common donor of both sublines in an 
earlier generation. 
Three other 5T MM were shown to be able to grow in the peritoneal cavity of 
unprimed recipient mice: 5T14, 5T30 and 5T33 MM. The DNA isolated from the 5T30 
and 5T33 MM showed only the germ line configuration, while that of the 5T14 MM 
produced an additional band of 1.3 kb (Hindlll) and 5.8 kb (EcoRI) (Fig. 3). 
23.7-
9.46 -
6.67 -
4.26-
2.25- ' 
1.96 -
2 3 4 5 6 7 8 9 
Figure 3. Autoradiogram of DNA from ascitic cells digested with Hindi// (lanes 1 - 5) and EcoRI (lanes 
6- 9). Lane 1: 5T2; lanes 2 and 6: 5T14; lanes 3 and 9: 5T33; lanes 4 and 8: RPC-20; lane 5: normal 
bone marrow cells. Analysis of 5T30 MM is not shown. 
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DISCUSSION 
The most common structural alteration in human Burkitt's lymphoma, mouse 
plasmacytoma and rat immunocytoma is an interruption of the c-myc gene upstream 
of its second exon (Mushinski et al., 1987). In many MPC, the breakpoint is within the 
first intron between E1 and E2, in some MPC, the breakpoint in c-myc occurs 300 to 
500 base pairs 5' of E1 (Potter, 1986). This kind of abnormality, indicated by a 
rearrangement of the c-myc oncogene within the bone marrow tumor cells of the 5T 
MM series was found only in the 5T2 MM bearing mouse in the 24th transplantation 
generation and in none of the seven other 5T MM, which were of earlier generations. 
The bone marrow is the major site of this malignancy in both man and the C57BL 
mouse (Radl et al., 1988). Therefore, any structural abnormalities within different onco-
genes, if they were of basic importance for the development of this malignancy, should 
primarily be present in the MM cells of the bone marrow compartment. In humans, 
rearrangement of the c-myc oncogene was found only in three cases (one of them 
being a very progressive lgA MM involving pleural tissue) and in one case of plasma 
cell leukemia (Gazdar et al., 1986; Selvanayagam et al., 1988; Yamada et al., 1983). 
In this context, it is interesting that in the 5T14 MM, being able to grow in the peritoneal 
tissue, a rearrangement of the c-myc was found in ascitic cells but not in the bone 
marrow cells. Moreover, the 5T2 MM in an advanced stage can develop features of a 
plasma cell leukemia (Ebbeling et al., 1985). These findings indicate that structural 
abnormalities of the c-myc oncogene of the most common MPC types are not a 
prerequisite for the development of MM. Our data, together with those of others on 
human MM, can be interpreted as indicating that such rearrangement can take place, 
possibly as a late event in the progression of this malignancy or due to its location in 
peritoneal or pleural tissue, where it can obtain selective growth advantage. Our 
investigation does not exclude some other structural abnormalities which would occur 
outside the analyzed region. 
Cytogenetic investigations performed in this multiple myeloma of the 5T series 
(Van den Akker et al., in preparation) showed near triploid chromosome numbers in 
4 lines (5T2, 5T7, 5T14 and 5T41) and hypotetraploid numbers in one (5T33). All 
karyotypes showed 1 or 2 copies of normal chromosome 15 and markers involving 
chromosome 15. 5T2 and 5T14 (transplant generation 11) showed markers with partial 
deletion of chromosome 15. No consistent abnormalities involving chromosomes 6, 12 
or 16 with the three immunoglobulin gene loci were found. To detect more subtle 
changes, if present, within the first exon of the myc gene, studies on the myc RNA 
message will be performed after establishing cell lines of the 5T multiple myelomas in 
vitro (work in progress). 
The human MM and the mouse 5T MM show a close resemblance in several 
aspects (Radl et al., 1985; Radl et al., 1988), including possibly also the c-myc pattern. 
Therefore, these 5T MM series offer an excellent experimental model for studies on the 
etiology and pathogenesis of multiple myeloma. In addition, this mouse B-cell malig-
nancy, expressed mainly at the differentiation stage of a plasma cell, shows clear-cut 
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differences when compared with MPC and RIC, both also involving a B cell at its last 
differentiation stage (Radl et al., 1988). Investigation of these differences may shed new 
light on possible microheterogeneity of the plasma cell and its malignant counterparts 
evolving either into local plasmacytoma or diffuse multiple myeloma. 
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ABSTRACT 
Genetic alterations that lead to the clonal expansion of differentiated cells in 
multiple myeloma have still to be elucidated. Many chromosomal aberrations have 
been found, but until now, none of them is typically associated with multiple myeloma. 
In search for genetic defects in multiple myeloma we studied the structure and 
expression of the c-myc oncogene and the pvt-like region because of their frequent 
association with other B-cell malignancies. Here we report co-amplification of the 
c-myc oncogene and the 5' part of the pvt-like region in two out of 26 cases of multiple 
myeloma. In both cases only K:-light chains were produced. The amplification 
manifested itself also at the RNA level. Total RNA was analyzed in one of these two 
cases showing abundant c-myc mRNA. In the same RNA sample we also detected a 
strong hybridizing band of about 7 kb, when the pSS.4 probe, representing the 5' 
part of the pvt-like region, was used. This band was not present in total RNA from 
normal bone marrow cells or bone marrow from multiple myeloma patients without the 
amplification of c-myc and the pvt-like region. Until now, transcripts of the pvt-like 
region were only found in a few human cell lines ranging in size from 1 to 11 kb. This 
is the first case in which a high expression of an about 7 kb transcript of the pvt-like 
region is found in freshly obtained tumor material, probably due to a pvt-amplification. 
The occurrence of abnormalities in the c-myc and the pvt-like regions in advanced 
cases of multiple myeloma suggests their involvement in the progression of this type 
of tumor. 
Submitted for publication. 
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INTRODUCTION 
Multiple myeloma (MM) is a B-cell neoplasia characterized by the clonal 
expansion, mainly in the bone marrow (BM), of malignant plasma cells producing a 
monoclonal immunoglobulin (lg) (Mellstedt et al., 1984; Barlogie & Alexanian, 1986). 
The genetic alterations involved in the neoplastic transformation in MM are still 
unknown. Evidence for the presence of activated cellular oncogenes have been shown 
in several human malignancies but for MM the involvement of oncogenes remains 
unclear. This is probably due to the low proliferative activity of myeloma plasma cells 
which makes it difficult to obtain adequate metaphase chromosomes and to establish 
representative cell lines (Latreille et al., 1982; Durie et al., 1985; Katagiri et al., 1985; 
Gazdar et al., 1986; Jernberg et al., 1987). Many different chromosomal aberrations 
have been found, but until now none of them is typically associated with MM (Lewis 
& MacKenzie et al., 1984; Ferti et al., 1984; DeWald et al., 1985; Ranni et al., 1987). 
As cytogenetic studies didn't lead to any clue which genes might be involved in MM, 
we searched for alterations in genes that are known to be associated with other B-cell 
malignancies, c-myc and pvt. In this context, the best described gene is the c-myc 
oncogene. The c-myc oncogene is often structurally altered in human Burkitt's 
lymphoma and in mouse plasmacytoma (Potter & Mushinski, 1984; Croce & Nowell, 
1985). In rare occasions, c-myc was also found to be altered in MM andjor human 
MM derived cell lines and in one 5T mouse MM line (Sumegi et al., 1985; Gazdar et 
al., 1986; Meltzer et al., 1987; Selvanayagam et al., 1988; Pegoraro et al., 1989; Radl 
et al., 1990). 
The human pvt-like region is situated about 300 kb distal from the c-myc gene 
and is frequently involved in t(2;8) translocations, occurring in variant Burkitt's 
lymphomas (Mengle-Gaw et al., 1987). The human pvt-like region is homologous to 
the mouse pvt-1 and the rat mis-1 gene, which are frequent proviral integration sites 
in retrovirally induced lymphomas (Graham et al., 1985; Graham & Adams, 1986). In 
mouse plasmacytomas with t(6; 15) translocations, most of the breakpoints cluster in 
the pvt-region, resulting in relocation of the C~~:-locus from chromosome 6 to the 
pvt-region on chromosome 15 (Banerjee et al., 1985; Cory et al., 1985; Graham et 
al., 1985). Possibly in mice there is a functional relationship between the c-myc proto-
oncogene and the pvt-1 locus, in which pvt regulates the transcription of c-myc over 
a long distance (Adams et al., 1986). Transcripts of the pvt-locus have only been 
found recently in a variety of human cell lines (Shtivelman & Bishop, 1989; Shtivelman 
et al., 1989), indicating that this locus indeed contains a functional gene. In human 
MM, involvement of the pvt-locus has not been explored. Therefore we searched for 
alterations in this gene and the c-myc gene in 26 MM BM samples. 
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Table 1. Clinical and molecular features of 26 patients with multiple myeloma. 
r--..:!~nt %PC Paraprotein JH re- c-myc pvt-1 amplification 
arrangement amplification pSS.4 pJBL.BR1 pJBLSS15 
1 (normal BM) 5 
2 87 lgG-A R 
3 22 lgG-~ R 
4 25 lgA-A R 
5 50 lgG-A R 
6 15 lgG-~ R 
7 39 ~ 
8 45 lgG-~ R x3 
9 30 lgG-~ R 
10 30 lgA-~ R 
11 15 lgG-~ 
12 34 ~ R 
13 90 A 
14 35 lgG-~ 
15 <1 lgG-A 
16 20 ~ R, A A 
17 75 lgA-~ R 
18 12 lgA-~ R 
19 58 A 
20 24 lgG-~ 
21 2 >90 lgG-~ R 
22 76 lgA-~ R 
23 50 ~ R 
24 30 ~ R 
25 60 ~ R A A 
26 95 ~ R 
Abbreviations: R, rearranged; A, amplified; X, extra band; PC, plasma cells; -, not detected. 
1) rearranged band is very weak. 
2) blood sample from a patient with plasma cell leukemia. 
3) extra band of undetermined significance. 
RESULTS 
DNA analysis 
Immunoglobulin genes. Analysis of lg gene rearrangement has helped to 
determine the clonality and differentiation stage in lymphoproliferative disorders 
(Siegelman et al., 1985; Griesser et al., 1986). When applied to BM samples from MM 
patients, discrete rearranged bands of the lg heavy-chain genes were observed in 
most cases when the DNA was digested with Bg/11 or EcoRI (Table 1 and Fig. 1). The 
intensity of the autoradiographic signal of rearranged lg gene bands corresponded 
with the degree of BM plasmacytosis, as estimated by immunofluorescent analysis. 
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Figure 1. Southern blot analysis of MM DNA digested with Bglll and EcoRI. 10 p.g DNA from the BM 
of 20 MM patients, one plasmacytoma patient (nr 21) and one normal control (nr 1) were digested with 
the indicated enzymes and hybridized to the indicated probes. The numbers correspond to the patient 
numbers in Table 1. The same filter was used for all hybridizations. 
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The appearance of rearranged lg bands in the total DNA extracted from the 
mononuclear cell (MNC) fraction of the BM samples, ensured us that the malignant 
clone could be detected which allowed us to detect abnormalities in the DNA from this 
clone. It should be noted that in some samples (patients nrs 7, 13, 14, 19 and 20) no 
rearranged JH fragment could be detected although the number of plasma cells was 
apparently high enough (see table 1) to expect detection of the rearranged lg gene. 
For patients nrs 13, 19 and 20 this could be due to the low amount of DNA present on 
the Southern blot but for patients nrs 7 and 14 some other explanation must be 
considered. The inability to detect clonallg rearrangements in some cases of MM is 
a phenomenon also observed by others (Humphries and Williams, 1989; Thielemans, 
personal communication). 
Myc gene. For c-myc gene analysis, the filters used for lg-analysis were 
rehybridized to the myc exon-3 probe. Rearranged bands were not detected in the 
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Figure 2. Southern blot analysis of MM DNA digested with BamHI. 10 fJ.Q DNA from four K.-LCD and one 
control was hybridized to the JH (A), the c-myc (B), the pJBLSS15 (C), the pJBL.BRI (D) and the pSS.4 
probe (E). The numbers correspond with the patient numbers in Table 1. The same filter was used for 
all hybridizations. 
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Figure 3. Schematic diagram of the pvt-like region. Probes representing different regions of pvt are 
depicted in a linear order on the chromosome. Restriction sites, R:EcoRI, H:Hind/11, 8: BamHI. 
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Figure 4. Northern blot analysis of myc and pvt mRNA from three MM patients. Approximately 15 J,Lg 
of total RNA were loaded per lane and hybridized with the c-myc, the pSS.4 and the GAPDH probe. HL60 
is a control cell line with known myc amplification. The numbers correspond with the patient numbers 
in Table 1. The same filter was used for all hybridizations. 
DNA samples tested. In two cases an amplification was found. The first was found in 
a case of ~>-light chain disease (LCD) (patient nr. 16, Fig. 1). The amplification was 
about 5 times as estimated from dilution experiments (data not shown). In a 
subsequent series of ~>-LCD cases, another case showing an amplification was found 
(patient nr. 25, Fig. 2). In this case the c-myc fragment was about 10 times amplified, 
as estimated from dilution experiments (data not shown). 
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Pvt-like region. To examine whether the DNA of MM showed rearrangements 
within the pvt-1 like region, the filters were rehybridized with the pSS.4, pJBL.BR1 and 
pJBLSS15 probes. The positions of these probes in the pvt-like region are shown in 
Fig. 3 in relation to the c-myc locus. In one DNA sample, digested with EcoR1 (patient 
nr. 8), an extra band was observed when hybridized with probe pSS.4. The intensity 
of this band corresponded with the intensity of the rearranged band detected with the 
JH probe, suggesting that it was derived from the malignant plasma cell clone. When 
the same DNA sample was digested with Bg/11, Hindlll, Sa/1, Xbal or BamHI, no extra 
band was observed (data not shown). Amplification of the pvt-locus was observed in 
the same two patients (nrs 16 and 25) that contained the c-myc amplification (Figs. 1 
and 2). The degree of amplification was in the same order of magnitude as for myc. 
In both cases, the amplification was only detected with probe pSS.4 and not with 
probe JBLSS15 or pJBL.BR1. 
RNA analysis 
The possibility that amplification of the c-myc gene was also reflected in 
enhanced levels of myc mRNA could only be analyzed in patient nr. 25. A Northern 
blot with total RNA from this patient, from normal BM and from a patient without an 
amplification was hybridized with the c-myc probe and the pvt-probe. The expression 
of c-myc mRNA was higher in patient nr. 25 as compared to patient nr. 8 and normal 
BM (Fig. 4). A pvt transcript of about 7 kb was detected with probe pSS.4 in patient 
nr. 25. No transcripts were found in normal BM and in patient nr. 8 (Fig. 4). 
Hybridization with probes pJBL.BR1 and pJBLSS15 also failed to reveal positive 
hybridization signals (data not shown). 
DISCUSSION 
In search for molecular mechanisms underlying the oncogenic event occurring 
in MM, we studied the structure and expression of the c-myc proto-oncogene. This 
gene is often deregulated in B-cell tumors of mouse and man. Indeed, we were able 
to show that the c-myc gene is amplified in two out of 26 cases of MM. It is of interest, 
that in both cases, only ~~;-light chains were produced and progression of the disease 
was aggressive. Rearrangement or amplification of c-myc is not a common phenome-
non in MM. It has only been found in those cases in which the disease was already in 
an advanced stage with plasma cells in the pleura or in the blood (Gazdar et al., 1986). 
This suggests activation of the c-myc proto-oncogene as a late event step, promoting 
the clonal evolution of a more malignant cell variant. The amplification of the c-myc 
gene resulted in a high expression of myc mRNA in at least the one case that could 
be analyzed. Because of the association of c-myc expression with pvt-1 alterations in 
murine plasmacytomas with t(6;15) and in murine T lymphomas with proviral 
integrations in pvt-1 (Cory et al., 1985; Tsichlis et al., 1989), we studied the structure 
of the pvt-1 locus in the same 26 patients. Amplification of this region was detected 
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in the same cases as in which a c-myc amplification was found. Amplification 
concerned only the most 5' part of the pvt-like locus, as it could only be detected with 
probe pSS.4 and not with two probes specific for sequences more distal from the 
c-myc gene. 
Amplifications of the pvt-like region together with c-myc amplifications have 
already been found in various cell lines from small cell lung carcinomas, a large cell 
lung carcinoma cell line and a colon carcinoma cell line (see Mengle-Gaw & Rabbits, 
1987), and also in a case of acute non-lymphocytic leukemia (Asker et al., 1988). In 
three cases, the c-myc amplification terminated within the pvt-like region. Whether the 
c-myc and pvt amplification represent the same amplicon in these two cases of MM 
was not examined, but is likely because the magnitude of amplification was the same 
for myc and pvt. 
Rearrangements involving the pvt-like region, as in variant Burkitt's lymphoma 
(Mengle-Gaw & Rabbitts, 1987), were not detected in this study. The origin of the extra 
pSS.4 band, observed in patient nr. 8, is unclarified. As the intensity of the band was 
similar to the rearranged JH band, it was probably derived from the malignant clone. 
However, it did not occur in hybridization patterns using other restriction enzymes like 
BamHI, Xbal, Sail, Hindlll or Bg/11. This extra band might be due to a small mutation 
in the pvt-like region, resulting in an EcoRI polymorphism. The c-myc expression in 
this case did not differ from that observed in the other patients (data not shown). 
Whether the co-amplification of c-myc and the pvt-locus has any implications 
for tumor development in MM, remains to be analyzed. Amplifications of N-myc in 
neuroblastomas and c-myc in small cell lung cancer are correlated with a poor 
prognosis (Brodeur et al., 1984; Little et al., 1983; Seeger et al., 1985). The c-myc 
gene encodes a nuclear protein that appears to be involved in DNA synthesis (Classon 
et al., 1987). Interference with normal level of c-myc expression can block the 
programmed transition of the cell to the resting state and may thereby contribute to 
tumor progression (see Cole, 1986). Involvement of the pvt-like region in various 
tumors and cell lines suggests an important role in tumorigenesis. The relationship to 
the c-myc gene function is speculative. As in man the normal distance of the pvt to 
the c-myc locus is about 300 kb, regulation must be considered to take place over a 
long distance. The observation of an abundant pvt-transcript of about 7 kb in one 
patient confirms the existence of a functional pvt-gene, of which the product may be 
involved in regulation of c-myc transcription. Recently, pvt-transcripts ranging in length 
from 1.0-11 kb were found in a variety of human cell lines (Shtivelman & Bishop, 1989; 
Shtivelman et al., 1989). In our case, we could not detect other transcripts than the 
about 7 kb transcript, probably because normal expression of the pvt-locus is very 
low and only in case of an amplification, the expression reaches levels above the 
detection level of Northern blot analysis. In the two cases of MM presented here, 
c-myc and pvt appear to be deregulated in parallel, suggesting that they may be 
functionally related and that they probably both play a role in oncogenesis. In the other 
24 cases studied, c-myc and pvt do not seem to be involved in the oncogenesis of 
MM, which means that other, still unknown genes have to be responsible for tumor 
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formation. 
The mechanism of transformation that leads to the formation of MM has still to 
be elucidated. The fact that amplifications of c-myc and pvt are only found in advanced 
stages of MM, suggests that alterations in the c-myc and pvt-region may promote the 
clonal evolution of a more malignant plasma cell variant. 
MATERIALS AND METHODS 
Bone marrow samples 
BM aspirates were obtained from 24 MM patients. Mononuclear cells (MNe) 
were obtained from these samples by Ficoii-Paque (1.077 kg/1, Pharmacia, Uppsala, 
Sweden) density gradient centrifugation. The degree of marrow plasmacytosis was 
defined by immunological staining for cytoplasmic lg light chains as described (Van 
Dongen et al., 1987). A BM sample from a healthy donor served as control. The MNe 
samples were frozen and stored in liquid nitrogen. 
Nucleic acid analysis 
High-molecular weight DNA and total RNA were co-extracted from BM cells by 
a guanidine isothiocyanate method with cesium chloride modification (ehirgwin et al., 
1979). DNA was digested with restriction enzymes and electrophoresed on 0.7% 
agarose gels. The gels were transferred to Ny13 N Nytran filters (Schleicher and 
Schuell, Dassel, F.R.G.) in 10 x SSe (1 x SSe is 0.15 M Nael, 15 mM sodium citrate, 
pH 7.0). After blotting, the filters were rinsed in 6 x SSe before drying and baked for 
two hours at 8o·e. Hybridization was done in 0.5 M NaHP04 (pH 7.2), containing 1% 
bovine serum albumin (BSA, Boehringer, Mannheim, F.R.G.), 1 mM EDTA, 3% sodium 
dodecyl sulphate (SDS), and 200 JLg/ml salmon sperm DNA at 6s·e. Final washings 
were performed in 40 mM NaHP04, 1% SDS, 1 mM EDTA at 6s·e. Filters were rinsed 
in 100 mM NaHP04 and sealed in plastic bags. To remove hybridized probe, filters 
were rinsed in 0.4 M NaOH at 43•e for 20 min, followed by a rinse in 0.1 x sse; 0.1 
x SDS at 42 • e for 30 min. 
For Northern blot analysis, 15 JLg of total RNA was electrophoresed on a 1.0% 
agarose gel in the presence of 6% formaldehyde, blotted onto Zeta-Probe filters 
(Bio-Rad Laboratories Inc., Richmond, eA) and hybridized in 10% dextran, 50% 
formamide (Maniatis et al., 1982) with 0.5% SDS at 42%e. Final washing was 
performed in 0.2 x sse; 0.5% SDS at 6s·e. To remove hybridized probes, filters were 
rinsed in boiling 0.01 x SSe; 0.01% SDS 4 times for 2 to 3 min. 
DNA probes were labeled according to Feinberg & Vogelstein (1983). Autoradio-
graphy on X-ray films was performed at -7o·e for various lengths of time. 
Gene probes 
To detect structural abnormalities in the c-myc gene, we used a 1.6 kb 
C/ai-EcoRI fragment consisting of the third exon and the 3' flanking sequences of the 
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human c-myc gene (Dalla-Favera et al., 1983), and 3 probes for the pvt-1 like region, 
pSS.4, pJBL.BR1 and pJBLSS15 (kindly provided by Dr. T.H. Rabbitts, see 
Mengle-Gaw and Rabbitts, 1987). 
Immunoglobulin gene rearrangements were examined with a 2.4 kb Sau3A 
fragment containing the human JH 2-6 region (Siegelman et al, 1985). 
The GAPDH (a 0.8 kb EcoRI-Pstl fragment; Benham et al., 1984) probe served 
as a control for the amount of RNA per lane in the Northern blot analysis. 
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ABSTRACT 
To study oncogene expression in heterogeneous cell populations we developed 
and optimized a non-radioactive in situ hybridization technique using biotinylated 
single-stranded RNA probes and combined this technique with immunofluorescent 
staining of cell surface markers. As a model for our studies we used HL60 cells. In 
these cells we detected c-myc mRNA molecules by in situ hybridization following 
staining of the pan myeloid cell surface marker CD33, by a monoclonal antibody. Hy-
brids were detected by streptavidin-FITC and CD33 by a TRITC-conjugated anti- body. 
Controls involved pretreatment with RNAse, hybridization with sense RNA probes and 
blocking with an excess of unlabeled antisense probes. The integrity of the RNA in 
the cell was shown by hybridization with the GAPDH antisense probe. Essential for 
successful double-labeling was the choice of a fixation procedure that was suitable 
for the in situ hybridization and mild enough not to destroy the cell surface marker 
staining. This fluorescent in situ hybridization in combination with cell surface marker 
staining will be useful for studying gene expression in phenotypically well-defined cell 
populations. 
Oncogene 4, 1255-1262, 1989. 
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INTRODUCTION 
The detection of RNA sequences within individual cells by in situ hybridization 
(ISH) allows the analysis of gene transcription at the single cell level. Although Northern 
and dot blot analyses of heterogeneous cell samples can provide important qualitative 
data on gene expression, these methods are not sensitive enough to detect a mRNA 
that is present in less than about 5% of the cell population. Moreover, these techniques 
do not allow one to differentiate between samples in which only a few cells have a high 
gene expression and samples in which the majority of the cells have a relatively low 
expression of the gene under study. The ISH technique, on the other hand, is more 
informative and more suitable in those cases where only a few cells are available for 
analysis andjor only a few cells express the gene of interest. A combination of ISH to 
detect oncogene expression and cell surface marker staining to phenotype the cells 
may be an extremely powerful diagnostic tool in cancer, especially in hemato-oncology. 
By using non-radioactive probes, the ISH can be easily performed in a routine fashion 
as these probes are easy to handle and to detect, and can be stored for an extended 
period of time. The use of biotin-labeled probes, labeled by nick translation or random 
primer methods (Coghlan et al., 1985) or in RNA polymerase systems (Hoefler et al., 
1985) is currently the most explored method and several detection systems are now 
available. These non-radioactive DNA or RNA probes have mainly been used to detect 
DNA targets (Bhatt et al., 1988; Garson et al., 1987; Hopman et al., 1986; Lawrence 
et al., 1988). Studies on detection of mRNA sequences are still scarce and most 
reports deal with the detection of abundant mRNA species (see e.g. Dirks et al., 1988; 
Bauman et al. (1988); Singer et al., 1986). Only a few investigators reported on the 
detection of low copy number mRNA molecules by using RNA probes and a fluo-
rescent detection system (Bresser et al., 1987). These systems are claimed to detect 
oncogene expression in haematopoietic cells for as few as 5 copies per cell. We 
explored this method and determined the conditions that can permit simultaneous 
detection of cell surface markers and specific mRNA sequences in the individual cell. 
In this report we describe the detection of c-myc expression in HL60 cells, a 
promyeloid leukemia cell line, in combination with the cell surface marker CD33. This 
was done by first labeling the cells with a monoclonal antibody (MoAb) followed by ISH 
with a biotinylated RNA probe. 
RESULTS 
Biotin-labeling of RNA probes 
Comparison of the labeling of RNA probes with bio-11-UTP, allyi-UTP or 
photobiotin revealed that the amount of RNA probe synthesized was about 4-7 JLg RNA 
per 1 JLg template when unlabeled UTP was used. In the presence of bio-11-UTP 
instead of unlabeled UTP, the yield of RNA was about four times lower, probably due 
to inefficient incorporation of bio-UTP by the RNA-polymerase. The allyi-UTP could be 
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Figure 1. Direct-spot assay of biotin-labeled RNA. Comparison between biotin-labeling with (1) bio-
UTP, (2) allyi-UTP, (3) photobiotin once and (4) photobiotin twice. The right column shows the yield of 
RNA transcripts. 
incorporated more efficiently into RNA, resulting in a yield of about 3-8 JLg RNA per 1 
JLg template. After photobiotinylation of the unlabeled probe and the attachment of a 
biotin-group to the allylamine labeled probe with the CAB-NHS ester the probes were 
compared for detectability by spotting them onto nitrocellulose. The bio-11-UTP labeled 
probe and the allyi-UTP labeled probe were both readily detectable at the 5 pg level 
(fig. 1). The photobiotinylated RNA probes were detectable at levels ranging from 10 
pg to 1 ng. Labeling with photobiotin for a second or third time increased the level of 
biotinylation but caused considerable loss of RNA probably due to the precipitation 
steps involved as well as to degradation of the RNA during the photobiotinylation step. 
In order to get large amounts of well-biotinylated probes we therefore choose to use 
allyi-UTP for subsequent experiments. 
Probe specificity 
Northern blots with total RNA from HL60 and other cell lines were hybridized 
with 32P-Iabeled myc antisense or sense RNA probes. The antisense probe detected 
the specific myc mRNA band of 2.3 kb. No cross-hybridization was observed with the 
ribosomal RNA bands. No signal was detected when the sense probe was used (fig. 
2). Spotblots containing antisense and sense myc RNA and myc DNA were hybridized 
with biotin-labeled myc sense and antisense RNA probes. Hybridization signals were 
observed only with complementary RNA spots and DNA spots (data not shown). The 
antisense GAPDH RNA probe detected the 1.2 kb mANA band on a Northern blot 
while the sense GAPDH probe did not (data not shown). The probes used were all 
degraded by limited alkaline hydrolysis. The time needed to degrade the probe to 
about 100-200 nucleotides varied between 30 and 60 min for the myc RNA probe 
dependent on different synthesis batches of the same probe. Therefore the length was 
checked at different hydrolysis time points. An example is shown in fig. 3. 
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Figure 2. Filter hybridization of sense and 
antisense myc RNA probes to total RNA from 
HL60 and K562 cells. Only the antisense probe 
can detect the 2.3 kb myc mRNA. 
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Figure 3. Estimation of the length of biotin-
labeled antisense myc RNA probe by Northern 
blot analysis at different time points during 
alkaline hydrolysis. The RNA is detected with 
streptavidine-alkaline phosphatase (8/uGENE, 
BRL). Size markers are depicted on both sides. 
Simultaneous detection of mANA transcripts and cell surface markers 
To develope an oncogene in situ hybridization in combination with cell surface 
marker staining we used HL60 cells as a model since these cells are known to express 
the myc oncogene at a high level (Westin et aL, 1982). The myc and the GAPDH RNA 
probes were used, in combination with the CD33 MoAb My9, to determine which 
fixative should be used and which conjugates for detecting the MoAb and biotin-label-
ed hybrids were the best Several storage procedures of cells and slides were tested 
to determine which procedure was the best in terms of RNA and surface marker 
retention. 
FIXation. The best results were obtained with 4% PF fixation. Cell morphology 
and RNA retention were good, which is in agreement with the findings of Lawrence et 
aL (1985). Also the labeling with the MoAb against CD33 was well preserved (see next 
section). The ISH signals on ethanol/glacial acid and methanol/acetone fixed cells 
were found to be variable and as glutaraldehyde fixation was not useful because of 
severe autofluorescence we choose PF fixation for further experiments. It should be 
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remarked that only cytocentrifuge preparations with a good cytomorphology as 
determined by phase-contrast microscopy resulted in optimal ISH signals. Therefore, 
cytocentrifuge preparations were checked for their quality before they were subjected 
to the ISH procedure. 
Detection. The detection of the CD33 MoAb My9 with a tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated antibody was in favor above a fluorescein 
isothiocyanate (FITC)-conjugated antibody because there was a considerable loss of 
FITC-Iabel during the ISH procedure, especially during the hybridization step in 50% 
formamide at 42·c. Although there was also some loss ofTRITC-Iabel, it was less con-
siderable than when using the FITC-Iabel. Reducing the hybridization time from 16 
hours to 4 hours, resulted in hardly any loss of TRITC-Iabel but in this case the ISH 
signal was lower. This could be resolved by increasing the probe concentration from 
1 ngj JLI to 1 0 ngj JLI. However, in order to save probe we choose the overnight 
hybridization method. The CD33 staining could be increased by using a second 
unlabeled rabbit anti-mouse antibody and a third TRITC-conjugated goat anti-rabbit 
antibody. However, a slight reduction of the ISH signal was found due to the larger 
time period needed for the labeling procedure in which endogenous RNAse could 
decrease the ISH. 
The best conjugate for the detection of intracellular biotinylated hybrids 
appeared to be the streptavidine (SA)-FITC from Zymed. The use of avidine-FITC 
resulted in high nonspecific nuclear staining. The use of anti-biotin antibodies and 
extravidine-FITC resulted in weaker signals. In order to enhance the ISH signal SA-
FITC was added before the washing procedure which would allow the formation of a 
complex of SA-FITC with intracellular bound and unbound biotin-labeled probe as 
stated by Bresser et al. (1987). In our hands this procedure increased the background 
to such a level that discrimination between specific and non-specific binding was no 
longer possible. The removing of excess probe before adding SA-FITC resulted in a 
weaker signal but the signal : noise ratio was much better. The use of acetic anhydride 
increased the signal : noise ratio even further. 
Storage procedures. Cytocentrifuge preparations were stored at different 
steps during the fixation: before fixation (dry at room temperature), after fixation in 70% 
ethanol at 4•c, and after the graded alcohol series (dry at room temperature). It 
appeared that after fixation in 4% PF the slides could be stored for at least 2 month in 
70% ethanol at 4 ·c without significant loss of ISH signal or surface marker staining. 
For optimal results cytocentrifuge preparations of the cells should be made within 2 
hours after harvesting. In the meantime the cells should be kept on melting ice at high 
density. After centrifugation, the slides could be kept dry at room temperature for 
several hours without any decrease of signal. But after 2 days the signal became 
weaker. The slides could also be stored dry at room temperature after passing through 
the whole fixation procedure ending with dehydration in graded alcohols. Also in this 
case the signal changed and became more diffuse after 2 days. The best and most 
convenient way was to fix the slides immediately and store them in 70% ethanol at 4 • C 
until needed. Good ISH signals were obtained also with cells that had been stored in 
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Figure 4. In situ hybridization of HL60 cells with biotinylated RNA probes. A: antisense GAPDH probe 
(1 ngjJLI); B: sense GAPDH probe (1 ng/JLI); C: RNAse treated cells, antisense GAPDH probe (1 ngjJLI); 
D antisense myc probe (1 ngjJLI); E: sense myc probe (1 ng/JL/); F: RNAse treated cells, antisense myc 
probe. 
Figure 5. In situ hybridization of CD33 labeled HL60 cells. A- phase-contrast morphology; B: CD33 
staining (TRITC); C: antisense myc probe (1 ngjJLI, FITC). The three micrographs represent the same 
field. 
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liquid nitrogen provided that extra care was taken in the thawing procedure to minimize 
cell death. 
Staining patterns 
GAPDH. The antisense GAPDH probe (1 ngftLI) was used as a positive control 
probe for the ISH studies. In every cell this GAPDH mRNA has to be present. Virtually 
all HL60 cells hybridized with this probe showed a cytoplasmic fluorescent staining 
indicating a good retention of mRNA (fig. 4A}. The signal had a patch-like pattern with 
often a more intense staining around the nucleus. Also some nuclear staining was 
observed which, in contrast to the cytoplasmic staining, turned out to be sensitive to 
RNAse treatment after hybridization. No hybridization signal was observed when the 
sense GAPDH probe (1 ng/J.LI) was used (fig. 48) or when the slides were first treated 
with RNAse (fig. 4C}. 
Myc. When using the antisense myc probe (1 ng/t.LI) a similar pattern of fluo-
rescent staining was seen in most cells (fig. 40). The specificity of the ISH signal was 
confirmed in three ways. First, hybridization with the sense myc probe (1 ng/ JLI) did not 
yield fluorescent staining above background (fig. 4E). Second, the signal was reduced 
by adding a high amount of unlabeled antisense myc RNA to the hybridization mixture 
(data not shown). Third, RNAse pretreatment prevented staining of the cells (fig. 4F). 
CD33 in combination with ISH. HL60 cells are known to express the CD33 
marker at a high level on the cell surface membrane (Paietta et al., 1987). The marker 
was still detectable after the cells were taken through the ISH procedure. But only after 
enhancement of the signal by a second unlabeled antibody the speckled TRITe-
staining became apparent (fig. 5A). The myc mRNA was also detectable in these 
labeled cells (fig. 58). However, there was some loss of specific hybridization signal, 
probably due to RNAse contamination of the antibody preparations used and/or loss 
of cellular integrity during the labeling procedure in suspension. The same results were 
obtained when the antisense GAPDH probe was used together with the CD33 MoAb 
(data not shown). The CD33 staining did not cause any aspecific binding of the probes 
as no hybridization with the sense GAPDH probe occurred (data not shown). The 
same results were obtained when the antisense GAPDH probe was used together with 
the CD33 MoAb (data not shown). 
Detection of myc mRNA in PB samples 
To test whether this ISH procedure was also suitable for peripheral blood (PB) 
cells we hybridized mononuclear cells (MNC) of a chronic myelocytic leukemia (CML) 
patient with a lymphoblastic blast crisis, with the antisense and sense myc probes. 
With the antisense probe strong FITC fluorescent staining was seen in virtually all 
leukemic blast cells (fig. 68) implicating an overexpression of the gene. Hardly any 
signal was observed in the smaller surrounding cells, presumably T cells. No 
hybridization signal was observed with the sense myc probe, indicating, together with 
the appearance of negative cells in the antisense myc ISH, the specificity of the 
hybridization. 
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Figure 6. In situ hybridization of PB cells from a patient with CML-BC. A: Phase-contrast morphology; 
8: antisense myc probe (1 ng/J.LQ. Only the blast cells are expressing myc mRNA. 
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Figure 7. Quantitation of the mean number of myc mRNA copies per cell in different eel/lines by dot 
blot analysis. The hybridization signals were analyzed by a densitometer and compared to the myc copy-
standard (lane 5). Loss of RNA during the isolation step was determined by adding 3000 myc RNA 
copiesjce/1 to U266 (lane 3), having no detectable myc mRNA on his own (lane 2). The level of myc 
mRNA expression was about 200 copiesjce/1 in HL60 and 30 copiesjce/1 in K562. 
Calculation of the number of myc copies in HL60. K562 and U266 
Myc-specific hybridization signals on dot blots with total RNA from a fixed 
number of cells were compared to hybridization signals of a standard series of myc 
sense RNA, synthesized on the pGEM myc template (fig. 7). After analysing the signals 
by means of a video densitometer the myc copy-number could be calculated. HL60 
cells contained about 200 copies per cell, comparable to the findings of Holt et al. 
(1988). In our subline of K562 cells we calculated about 30 copies per cell which was 
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higher than the 5-10 copies present in the subline used by Evinger-Hodges et al. 
(1988). In U266 cells the level of myc mRNA was below our level of detection. To cal-
culate the loss of RNA due to the isolation procedure we added 3000 copies of myc 
sense RNA per cell to the U266 cell lysate. Dot blot analysis of U266 cells artificially 
made myc positive showed that there were about 3000 copies per cell, indicating that 
there was no substantial loss of RNA during the isolation procedure (fig. 7). 
DISCUSSION 
ISH is becoming a widely used technique to detect gene expression in individual 
cells. To determine more precisely the cell type in which the mRNA of interest is 
localized, a combination of ISH with immunofluorescent staining of surface or 
cytoplasmic antigens would be very useful. In this study we show that it is possible to 
detect myc mRNA in CD33 labeled HL60 cells. To obtain an optimal hybridization 
signal, the starting material was fixed and prepared in a way that leads to optimal RNA 
retention, tissue preservation, and accessibility of the probe. Several fixatives have 
been described in the literature that fullfil this purpose (see e.g. Singer et al., 1986; 
Dirks et al., 1989; Bauman et al., 1988). In our hands PF fixation gave the most 
reproducible results in terms of ISH signal and cell surface marker staining. 
The advantage of single-stranded (ss) RNA probes over double-stranded (ds) 
DNA probes includes a higher affinity and thermal stability of RNA-RNA hybrids 
(Angerer & Angerer, 1981; Cox et al., 1984, Meinkoth et al., 1984) which leads to 
increased sensitivity. Furthermore, competitive hybridization to the complementary 
strand, which can occur with dsDNA probes, is excluded with ssRNA probes. The use 
of plasmids containing two RNA polymerase promoters at both sides of the subcloned 
fragment makes it possible to produce large amounts of ssRNA transcripts in both 
orientations. 
Our ISH studies clearly revealed localization of both myc and GAPDH mRNA in 
the cytoplasm of HL60 cells. The specificity of the ISH was shown by several controls. 
First, hybridization with the sense myc and the sense GAPDH probe in the same 
amounts as the antisense probes did not reveal fluorescent staining. Second, RNAse 
pretreatment of the slides prevented hybridization. Third, adding of an excess of 
unlabeled antisense myc probe reduced the hybridization signal to background levels. 
Furthermore, the myc signal occurred only in the morphologically determined blast 
cells in a PB sample of a patient with a CML-BC and not in the non-malignant cells in 
the same sample. High expression of c-myc is known to occur in CML (Ferrari et al., 
1985), but not in normal PB cells and is probably indicative for the unregulated growth 
of the leukemic cells. These differences in levels of c-myc expression within the same 
sample provide a good internal control. With this ISH technique we can clearly detect 
myc mRNA in HL60 cells which indicates about 200 copies per cell as is shown by dot 
blot analysis. In K562 cells we observed also myc hybridization signals, which were 
clearly distinguishable from the myc negative U266 cells (data not shown). We estimate 
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therefore that we can detect with this technique about 30 copies per cell. 
The combination of ISH with immunocytochemistry has been described earlier 
(Brahic et al., 1984; Shivers et al., 1986; Dirks et al., 1988). Most of these papers 
concerned ISH on sections, using radioactively labeled probes and avidin-alkaline 
phosphatase cytochemistry or DAB cytochemistry. In this study we show that it is 
possible to use fluorescent labels for both the ISH detection and the surface marker 
staining of cell suspensions. Hybridization signals were slightly reduced as a 
consequence of primary and secondary antibody treatment, which takes time enabling 
RNA destruction by endogenous RNAse. Decrease of the ISH signal can also be due 
to RNAse contamination of the antibody preparations. To avoid this as much as 
possible, antibodies should be diluted in RNAse free buffers. For surface marker 
staining the TRITC label was in favor over the FITC label in terms of resistance to 50% 
formamide at 42·c overnight. 
Since we would like to use the ISH technique for routine analysis of oncogene 
expression in bone marrow and blood samples, we also investigated the best 
conditions for storing the cells and slides with minimal loss of ISH signal. It appeared 
that the best way to store the slides was first to fix the slides in 4% PF and sub-
sequently to store them in 70% EtOH at 4 ·c. Up to 2 months no reduction in ISH 
signal was observed. Especially for mRNA's with a short half-life such as myc, it is 
necessary to fix the cells as soon as possible. It has been reported that cytocentrifuge 
preparations, after fixation, can be stored air dry at room temperature for at least five 
months (Bresser et al., 1987). In our hands, however, by storing the slides air dry, the 
ISH signal decreased already after one week, which was not the case when the slides 
were stored in 70% EtOH at 4•c. Also cells stored in liquid nitrogen could be used for 
ISH studies, provided they were frozen rapidly after sampling and provided they were 
thawed very carefully. 
In conclusion, ISH can be performed conveniently using biotin-labeled RNA 
probes and fluorescence based detection methods. The combination of ISH with cell 
surface marker staining may become a useful diagnostic tool for early detection of 
malignancies in which overexpression of oncogenes occur which cannot be addressed 
by Northern blotting. Furthermore, the method enables one to determine whether a 
particular protein, present in a cell, is also produced by this cell itself and to study the 
relationship between the concentration of a particular species of mRNA and the 
amount of protein encoded by this mRNA. This method can also serve as a monitor 
of therapy which aims to down-regulate particular genes or to extinct cells with high 
oncogene expression. 
MATERIALS AND METHODS 
Cell lines. The HL60 promyelocytic leukemia cell line (Collins et al., 1977; 
Gallagher et al., 1979), the K562 chronic myelocytic leukemia cell line (Lozzio et al., 
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1975) and the U266 myeloma cell line (Nilsson, et al., 1970) were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 15% fetal calf serum (FCS; 
Boeringer, Mannheim, F.R.G.), penicillin (100 t£g/ml), streptomycine (100 t£g/ml), L-
glutamine (4mM) and HEPES (25 mM). Cells were maintained in log phase. 
Leukemic cell samples. Peripheral blood (PB) samples were obtained from 
a patient with a chronic myelocytic leukemia in blast crisis (CML-BC). The leukemic 
cells had a lymphoblastic morphology and expressed CD10 (VIL-A1). Mononuclear 
cells (MNC) from PB were isolated by Ficoii-Paque (density, 1.077 gjml; Pharmacia, 
Uppsala, Sweden) centrifugation. 
Molecular probes 
For ISH studies, single-stranded biotin-labeled antisense and sense RNA probes 
were prepared. DNA probes were subcloned in vectors containing RNA polymerase 
promoters. Vectors were linearized by digestion with suitable restriction enzymes that 
would cut just behind or in front of the subcloned fragment revealing templates for RNA 
production. For c-myc RNA production a 1.4 kb Clai-EcoRI fragment, containing the 
third exon of the human c-myc gene (Dalla-Favera et al., 1983), was subcloned into 
the pGEM-1 vector (Promega Biotec, Madison, WI). This vector contains the promoters 
for Sp6 and T7 polymerases. The template linearized by Hindlll digestion was 
transcribed with the T7 polymerase, yielding antisense transcripts. The template 
linearized by EcoRI digestion was transcribed with the Sp6 polymerase encoding sense 
transcripts. For GAPDH RNA production an 0.8 kb EcoRI-Pstl fragment (Benham et al., 
1984) was subcloned into the bluescribe vector (Vector Cloning System, San Diego, 
CA). This vector contains the promoters for T7 and T3 polymerases. The template 
linearized by digestion with Hindlll was transcribed with the T7 polymerase yielding 
antisense transcripts. The template linearized by digestion with EcoRI was transcribed 
with the T3 polymerase encoding sense transcripts. The transcriptions were performed 
as suggested by the manufacturer except for the concentration of the ribonucleotides 
which was increased 2-fold to 1 mM, the amount of enzyme was doubled and after 
each 15 min 5 additional units of polymerase were added. The reaction was allowed 
to continue for 2 hours at 4o·c (Melton et al., 1984), resulting in full length transcripts. 
The DNA template was then digested with DNAsel (Promega Biotec) and the probes 
were purified by centrifugation chromatography through a Sephadex-G50 column, 
eluted with 0.1 x SSC (1 x SSC is 0.15 M NaCI, 15 mM tri-sodium citrate, pH 7.0) 
containing 0.1% sodium dodecyl sulphate (SDS). The biotinylation of the probes was 
achieved either by replacing the unlabeled UTP by biotin-11-UTP (BRL, Gaithersburg, 
MD) in the synthesis reaction or by replacing the unlableled UTP by allylamine-UTP 
(BRL) followed by biotinylation of the allyl-group with a CAB-NHS ester (BRL) or with 
Photobiotin (Vestor Laboratories, Inc., Burlingame, CA) as suggested by the 
manufacturer. The RNA yield was measured under UV light by ethidium-bromide 
staining in comparison with a standard series of known RNA concentrations. The RNA 
yield ranged from 1 to 10 t'g RNA per t'g template. The biotinylation of the probes was 
checked by direct filters pot tests following directions as described for biotinylated DNA 
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probes (BiuGENE detection system, BRL), except for the RNA dilution which was 
diluted in 1 x sse, with 0.1 JLg/ JLI tRNA. The probes were degraded before use by 
limited alkaline hydrolysis (Cox et al., 1984) to a length of 100-200 nucleotides. To 
check the size of the probes they were electrophorized through a 2% agarosejformal-
dehyde gel, together with biotin-labeled ssRNA molecular weight markers. These 
markers were prepared on templates containing a 60 bp fragment and a 140 bp 
fragment. The gel was transferred to a nitrocellulose membrane filter and visualized 
according to the BluGENE system (BRL) with streptavidin-alkaline phosphatase (SA-
AP). The specificity of the RNA probes was checked on Northern blots containing total 
cellular RNA extracts from HL60 cells. The RNA probes used for this purpose were 
labeled with [32P-]a-CTP (800 Ci£mmol; Amersham, UK) according to the manufac-
turer. The incorporation of the e P]a-CTP was about 75% and the specific activity of 
the probe was about 5 x 1 o8 dpm/ JLg. Probes were stored in 0.1 x sse, 0.1% SDS at-
1o·c. 
In situ hybridization (ISH) 
Labeling of cell surface membrane markers. Cells were washed twice in 
phosphate-buffered saline (PBS, pH 7.8) containing 0.5% bovine serum albumin (BSA; 
Boehringer), counted, and adjusted to 10 x 106 cells per mi. HL60 cells were incubated 
with the CD33 murine monoclonal antibody (MoAb) My9 (Coulter Clone, Hialeah, FL) 
and subsequently with a TRITC-conjugated goat anti-mouse lg antiserum (Central 
Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands) as a 
second-step reagent as described elsewhere (Van Dongen et al., 1987). The signal 
could be enhanced by using a rabbit anti-mouse lg antiserum (Nordic Immunological 
Laboratories, Tilburg, The Netherlands) as a second-step reagent and a TRITe-
conjugated goat anti-rabbit antiserum (Supertechs, Bethesda, MD) as a third-step 
reagent. Labeled cells were cytocentrifuged (Cytofuge, Nordic Immunological 
Laboratories) on ethanol pre-cleaned slides, air-dried at room temperature for about 
15 min and fixed immediately. 
Fixation. Several fixatives for fixation of the cytocentrifuge preparations were 
tested: 1) ethanoljglacial acetic acid (80:20) for 10 min, followed by 5 min in 96% 
ethanol and air-dried, 2) methanol/acetone (50:50) for 15 min and air-dried, 3) 4% 
paraformaldehyde in PBS (pH 7.8) containing 5mM MgCI2, followed by at least 15 min 
in 70% ethanol at 4 ·C. 
Acetylation. Fixed slides were washed in PBS 5mM MgCI2 (pH 7.8) for 15 
min; acetylated in freshly prepared 0.25% acetic anhydride in 0.1 M tri-ethanolamine 
(pH 8.0) for 10 min (Hayashi et al., 1978; Hoefler et al., 1986), washed in 2 x sse for 
1 min, washed in PBS-5mM MgCI2 for 1 min, treated with 0.1 M glycine in 0.1 M Tris-
HC1 (pH 7.0) for 30 min, washed in 2 x sse for 10 min, dehydrated for 5 min each 
through 70%,80%,95%, 100% ethanol. Finally the slides were air-dried and hybridized. 
Hybridization. Slides were preincubated with 15 JLI of 50% deionized 
formamide (Merck, Darmstadt, F.R.G.) in 2 x SSC for 10 min and then hybridized with 
10 JLI hybridization mix containing the biotinylated probe (0.5-10 ng/JLI) diluted in a 
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hybridization buffer containing 50% deionized formamide, 5 X SSC, 0.1 M sodium 
phosphate (pH 7.4), 1 mgjml E.coli tRNA (Boehringer), 10 mM dithiotreitol and 10 mM 
vanadyl ribonucleoside complexes (New England Biolabs, Inc., Westburg, The 
Netherlands). Hybridization was performed at 42°C in a chamber moistened with 50% 
formamide in 2 x sse for 16 hr. After hybridization, slides were washed twice with 1 
x sse containing 0.01% Triton for 15 min at 55°C and once with 0.5 x sse, for 15 min 
at 55°C. 
Detection. Several conjugates for biotin-detection were tested: streptavidine-
FITC (SA-FITC, BRL), SA-FITC (Pharmacia), SA-FITC (Zymed, San Francisco, CA), 
extravidine-FITC (Sigma, St. Louis, MO), avidine-FITC (E.Y. Laboratories, San Mated, 
CA) and anti-biotin-FITC (Sigma). Fifteen JLI of optimally titrated (often an 1:50 dilution) 
conjugate (in PBS-0.5% BSA) were applied to the cells and the slides were incubated 
for 30 min in a moist chamber. Excess of conjugate was removed by a wash in PBS-
5mM MgCI2 (pH 7.8) for 15 min. The slides were embedded in an antifade solution 
consisting of 90% glycerol in PBS (pH 8,6) and either 100 mgjml 1 ,4-diazobicyclo-
(2,2,2)-octane (DABCO) or 1 mgjml p-phenylenediamine (BDH Chemicals, Poole, UK). 
Controls. The specificity of the ISH was tested by several controls. First: by 
RNAse pretreatment. Cytocentrifuge preparations were fixed as described above but 
before they were dehydrated in graded alcohols incubated with RNAse A (Boehringer), 
100 JLg/ml in 2 x sse tor 30 min at 37"C. Subsequently the slides were washed 
extensively in 2 X sse and processed for hybridization as described above. Second: 
by adding a high amount of unlabeled antisense RNA probe to the hybridization 
mixture. The unlabeled probe concentration was 200 x more than the labeled probe 
cencentration. Third: by hybridization with the sense RNA probe. The preservation of 
RNA in the cells was tested by GAPDH hybridization. 
Microscopes. Zeiss (Carl Zeiss, Oberkochen, FRG) and Leitz (Ernst Leitz 
Wetzlar, FRG) microscopes were used for the evaluation of the fluorescence staining. 
The microscopes were equipped with HBO mercury lamps (Osram, Berlin, FRG), 
phase-contrast facilities and filter combinations for the selective visualization of FITC 
and TRITC. 
Storage. Several storage procedures for the cells and the cytocentrifuge 
preparations were tested. Cells were stored in liquid nitrogen in DMEM containing 40% 
FCS and 10% DMSO for time periods of several weeks up to several years, or cells 
were stored at 4 ° C or room temperature for a couple of hours to one night. 
Cytocentrifuge preparations were stored at different steps during the fixation: before 
fixation (dry at room temperature), after fixation in 70% ethanol at 4 oc, and after the 
graded alcohol series (dry at room temperature). 
Estimation of myc copy number 
Total RNA was isolated from 2 x 106 HL60 cells, K562 cells and U266 cells 
respectively according to Chirgwin et al. (1979). The RNA was spotted on nitrocellulose 
in a two-fold dilution, starting with one tenth of the isolated RNA, comparable to 2 x 105 
cells. Sense myc RNA, synthesized on the pGEM-myc template, was used as a 
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standard and spotted on nitrocellulose in a two-fold dilution starting with 73.33 pg, 
comparable to 1 x 108 copies myc RNA (our myc transcript is 1.4 kb). The filter was 
hybridized to a [32P]-Iabeled eDNA myc probe in 10% dextran, 50% formamide 
(Maniatis et al., 1982). Final washing was performed in 0.3 x sse, 0.1% SDS at 65·c. 
Hybridization signals of the different cell types were compared to the hybridization 
signal of the standard. The signals were analyzed by a densitometer (Bio-Rad 
Laboratories Inc., Richmond, CA}. The loss of RNA during the isolation procedure was 
estimated by adding a fixed amount of sense myc RNA to the lysate of 2 x 106 U266 
cells and scoring the amount of this sense myc RNA after isolation and spotting onto 
nitrocellulose by comparing the myc hybridization signal in U266 with the standard 
hybridization signal. 
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ABSTRACT 
Using fluorescent in situ hybridization together with cell surface marker staining 
we studied the expression of mRNA of IL-6 and mRNA of IL-1,8 in bone marrow 
samples from human multiple myeloma patients. It is known that IL-6 can stimulate B 
cell growth and differentiation. Recently it has been suggested that IL-6 is responsible 
for autocrine growth stimulation of myeloma cells. IL-1 may play a role in bone 
resorption. These interleukins have previously been detected in the supernatants of 
cultured myeloma cells. Here we report the expression of IL-1,8 mRNA by plasma cells, 
T cells and macr?phages according to morphology and immunologic marker analysis, 
suggesting that not only myeloma cells but also other cell types can contribute to the 
production of IL-1.8 and thus to bone-resorption. IL-6 mRNA could not be detected in 
plasma cells from bone marow aspirates but did occur in monocytes and T cells, 
suggesting that in vivo IL-6 stimulates the growth of myeloma cells in a paracrine 
instead of an autocrine way. 
Submitted for publication. 
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INTRODUCTION 
Multiple myeloma (MM) is a malignancy characterized by the clonal expansion 
of malignant plasma cells in the bone marrow (BM). These tumor cells produce a 
monoclonal immunoglobulin (lg) defined by its idiotypic determinants (1). Bone lytic 
lesions often occur in advanced stages of the disease. Myeloma cells in culture 
produce several cytokines which may be involved in the regulation of tumor growth 
and differentiation andjor the activation of osteoclasts. Especially interleukin-6 (IL-6), 
a potential growth factor forB-cell hybridomas (3), EBV-transformed B-lymphoblastoid 
cells, plasmacytomas and myeloma cells (2-6), is suggested to play a role in autocrine 
stimulation of myeloma cells (7), although direct evidence for this suggestion is lacking. 
The mechanism of bone destruction in MM is also a major point of investigation. 
Several cytokines are thought to be responsible for bone resorption in vitro, such as 
interleukin-1 (IL-1), tumor necrosis factor (TNFa), lymphotoxin (LT/TNF,B), and 
transforming growth factor .B (TGF,B) (10-13). These cytokines are found in culture 
supernatants of normal activated peripheral blood mononuclear cells. Garrett et al. 
reported that cultured human myeloma cells produce LT, not IL-1, and that the 
secreted LT may be responsible for bone destruction in MM (14). In contrast with 
Garrett's findings, Kawano et al. and Cozzolino et al. reported that cultured human 
myeloma cells do produce IL-1 which has bone resorbing activity (15,16). 
To investigate the capacity of myeloma cells to produce cytokines in the in vivo 
situation we performed in situ hybridization (ISH) on BM samples of MM patients to 
detect mRNA of IL-1,8 and IL-6 at the single cell level. We used biotinylated single 
stranded (ss) RNA probes for these two cytokines in combination with a fluorescent 
streptavidine conjugate. This was combined with cell surface marker staining to 
phenotype the cells. 
MATERIALS AND METHODS 
Bone marrow samples 
BM aspirates were obtained from 17 MM patients. Mononuclear cells (MNC) 
were isolated from these samples by Ficoii-Paque (1.077 kg/1; Pharmacia, Uppsala, 
Sweden) density centrifugation. The degree of marrow plasmacytosis was defined by 
immunological staining for cytoplasmic lg light chains as described (17). A BM sample 
from a healthy donor served as control. These MNC samples were frozen and stored 
in liquid nitrogen. 
Northern blot analysis 
Total RNA was isolated from MNC by a guanidine isothiocyanate method with 
cesium chloride modification (18). RNA (10 JLg) was electrophoresed on a 1% agarose 
gel in the presence of 6% formaldehyde, blotted onto Biotrans Nylon membranes 
(FCN, Irvine, CA) and hybridized in 10% dextran, 50% formamide (19) at 42·c. Final 
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washing was performed in 0.2 x SSG; 0.5% SDS at 65·c. To remove hybridized probe, 
filters were rinsed in boiling 0.01 x SSG; 0.01% SDS 4 times for 2 to 3 min. DNA 
probes (IL-1,8, 1.3 kb eDNA, Genetics Institute, Cambridge, MA, and IL-6, 0.3 kb eDNA, 
see ref. 20) were labeled according to Feinberg & Vogelstein (21 ). Autoradiography on 
X-ray films was performed at ?o·c for various durations. 
The GAPDH (a 0.8 kb EcoRI-Pstl fragment; 21) served as a control for the 
amount of RNA per lane in the Northern blot analysis. 
RNA probes 
IL-1,8 and IL-6 DNA probes were subcloned into the bluescribe vector (Vector 
Cloning System, San Diego, CA). RNA transcription, biotinylation and control of the 
probes were performed as described previously (23). Briefly, the vectors were 
linearized and transcribed with either T7 or T3 RNA polymerase (Boehringer, 
Mannheim, FRG) in the presence of allylamine-UTP (BRL, Gaitherburg, MO), CTP, 
GTP, and ATP. The allyl-group was biotinylated with a CAB-NHS ester (BRL). Probes 
were degraded by limited alkaline hydrolysis to a length of 100-200 nucleotides. The 
concentration of the probes used in the ISH ranged from 1 to 5 ngj JLI. 
In situ hybridization 
ISH was performed on cells which were stained by monoclonal antibodies as 
described previously (23). In brief, MNC were labeled with monoclonal antibodies 
against CD3(Leu-4; Becton Dickinson, San Jose, CA) to detect T cells, CD14 (My4; 
Coulter Clone, Hialeah, FL) to detect monocytes, RFD9 (Dr. L.W. Poulter, London, 
U.K.) to detect macrophages and CD38 (OKT10; Ortho Diagnostic Systems, Raritan, 
NJ) which is expressed on the surface membrane of plasma cells. A TRITC-Iabeled 
goat anti-mouse lg antiserum (Central Laboratory of the Blood Transfusion Service, 
Amsterdam, The Netherlands) was used as a second step to detect the immunologic 
markers. Data from the immunologic marker analysis of the BM samples from some 
MM patients studied in detail are shown in Table 2. For ISH, samples of labeled cells 
were cytocentrifuged and fixed in 4% paraformaldehyde for 1 min, and stored for at 
least 15 min in 70% ethanol at 4·c. Slides were acetylated, washed and treated with 
0.1 M glycine, again washed and dehydrated in a graded alcohol series. Air-dried slides 
were hybridized with biotin-labeled ssRNA probes in 50% formamide, 5 x sse, 0.1 M 
sodium phosphate containing 1 mgjml E.coli tRNA (Boehringer), 10 mM dithiotreitol 
and 10 mM vanadyl ribonucleoside complexes (New England Biolabs, Inc., Berkeley, 
CA) at 42·c overnight. After hybridization, slides were washed twice in 1 x sse, 0.01% 
Triton for 15 min at 55· C. The biotin-labeled hybrids were detected by streptavidine-
FITC (Zymed, San Francisco, CA) incubation for 30 min at room temperature. The 
slides were washed for 15 min in phosphate buffered saline (PBS) and embedded in 
an antifade solution consisting of 90% glycerol in PBS (pH 8.6) and 1 mgjml p-
phenylenediamine (BDH Chemicals, Poole, UK). 
The specificity of the ISH was checked as described (20-23). Only the antisense 
RNA probes detected a 1.8 kb IL-1,8 mANA or a 1.3 kb IL-6 mANA on Northern blots 
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as the sense probes did not. Integrity of RNA in the cell was checked by hybridization 
with the antisense GAPDH probe. Hybridization with the sense GAPDH probe served 
as a negative control. Only cells in which the hybridization signal was clearly higher 
than the background were scored as positive. 
Microscopes 
Zeiss (Carl Zeiss, Oberkochen, FRG) and Leitz (Ernst Leitz, Wetzlar, FRG) 
microscopes were used for the evaluation of the fluorescent staining. The microscopes 
were equipped with HBO mercury lamps (Osram, Berlin, FRG), phase-contrast facilities 
and filter combinations for the selective visualization of FITC and TRITC. 
RESULTS 
Expression of IL-18 and IL-6 in MM detected by Northern blot analysis 
IL-1.8 mRNA could be detected in 5 out of 17 BM samples from MM patients 
and in one normal BM sample (Table 1). In patients nrs. 1, 4 and 5 the expression was 
abundant (see also Fig. 1). In 12 BM samples we were not able to detect IL-1,8 mRNA 
probably due to the detection limit of Northern blot analysis. GAPDH hybridization 
Table 1 Clinical features and interleukin expression in 17 patients with multiple myeloma 
Patient Stage Paraprotein Bone-destruction %PC IL-1,8* IL-6* 
normal BM 5 + 
1 IIIB lgA/11: + 75 ++ + 
2 lA lgG/11: 15 + 
3 lA lgGj.A 23 + 
4 lilA lgGj.A + 55 +++ + 
5 IIA lgGj~~: ? 55 ++ 
6 IIIB lgA/11: + 30 
7 lA lgG/11: 30 
8 ? 11:-LCD + 39 
9 IIIB lgG/11: + 15 
10 IIA lgGj.A + 50 
11 ? lgAj.A ? 25 
12 IIIB lgGj.A + 22 
13 lilA lgGj~~: + 57 
14 lilA 11:-LCD + 34 
15 lilA lgA/11: 76 
16 IIA lgG/11: 68 
17 liB lgG/11: + 10 
Abbreviations: LCD, light chain disease; %PC, percent plasma cells per MNC; ?, not known; -, not 
detected. 
* Detected by Northern blot analysis; an example is shown in Fig. 1. 
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clearly revealed the presence of GAPDH mANA in these 12 BM samples (data not 
shown). IL-6 mANA could be detected in 2 out of 17 BM samples from MM patients 
(Table 1). These two BM samples revealed a high expression of IL-1.8 mANA. TheIL-
6 expression was much lower than the IL-1.8 expression. To see which cells were 
responsible for the production of these two interleukins we performed ISH on BM 
samples from three patients. 
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Figure 1. Northern blot analysis of four MM samples and one normal control probed with IL-1.8, IL-6 
and GAPDH probes. Abbreviation: NBM, normal bone marrow. 
Expression of IL-18 and IL-6 in MM detected by ISH 
We performed ISH on BM aspirates from patients nr 1, 2 and 3 (see Table 
2) and on one normal BM sample. IL-1.8 mANA was clearly present in morphologically 
defined plasma cells which were CD38 positive as shown in Fig. 2. There were also IL-
1.8+ cells present which were CD38-. 
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Figure 2- IL-1 in situ hybridization on CD38 labeled BM cells from a patient with MM. (a) antisense 
IL-1/3 probe (1 ngj[J.I, FITC); (b) CD38 staining (TRITC); (c) phase-contrast morphology_ The three 
micrographs represent the same field_ 
Figure 4_ IL-6 in situ hybridization on CD38 labeled BM cells from a patient with MM_ (a) antisense IL-
6 probe (1 ngj[J.I, FITC); (b) CD38 staining (TRITC); (c) phase-contrast morphology. The three 
micrographs represent the same field. 
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In double labeling studies with other markers it appeared that these IL-1,8+ 
cells were macrophages (RFD9+) and CD3+ T cells but not CD14+ monocytes (Fig. 
3A). The proportion of CD38+ cells that expressed IL-1,8 mRNA was at least twice as 
high in the three MM patients as in normal BM (Fig. 3A). Expression of IL-1,8 mRNA 
by CD3+ T cells in MM BM was also more frequently found than in normal BM (Fig. 
3A). Most of the RFD9+ macrophages expressed the IL-1,8 mRNA in contrast with the 
CD14 + monocyte population, in which less than 10% of the cells expressed IL-1,8 
mRNA. The distribution of CD38, CD3, CD14 and RFD9 positive cells in the separate 
BM samples is shown in Table 2. 
Table 2 Immunologic marker analysis of three MM cell samples and one normal BM sample 
Immunologic markers 
CD38 CD3 CD14 RFD9 
Cell samples (OKT10) (Leu-4) (My4) 
Normal BM 18 6 17 NT 
Patient 1 99 9 5 11 
Patient 2 35 9 20 20 
Patient 3 53 21 NT NT 
The figures represent percent positivity per MNC. The cell sample numbers correspond with the numbers 
in Table 1. NT, not tested. 
A o control B D control 1111 patient 1 100 1111 patient 1 
..!!! 100 Cl patient 2 
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20 
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Figure 3. Expression of /L-1,8 (A) and /L-6 (B) by the different cell types present in the BM sample. The 
percentage of /L-1,8 en /L-6 cells were estimated by counting the /L-1,8+ or /L-6+ cells within the 
population of cell surface marker positive cells (CD38, CD3, CD14 and RFD9 respectively). The 
distribution of CD38, CD3, CD14 and RFD9 in the different bone marrow samples is shown in Table 2. 
Abbreviations: PC, plasma cells; Mono's, monocytes; M¢, macrophages; *, not tested. 
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IL-6 expression was analyzed in one patient (nr. 1}. IL-6 mRNA was only 
detected in small cells which where CD38-. The CD38+ plasma cells were clearly IL-
6- (Fig. 4). The IL-6+ cells appeared to be monocytes (CD14 +) and T cells (CD3 +)as 
analyzed by double labeling studies (Fig. 38). 
DISCUSSION 
In this study we have examined the cellular localization of IL-1,8 and IL-6 
mRNA in BM samples of MM patients. By Northern blot analysis we could detect IL-
1.8 mRNA in five out of seventeen MM samples and in one normal BM sample. Two of 
these five IL-1.8 mRNA + MM samples expressed also IL-6 mRNA, although weak. The 
cell type(s) responsible for expression of IL-1.8 mRNA and IL-6 mRNA were identified 
by double fluorescent ISH. Plasma cells, macrophages and T-cells were found to 
express IL-1.8 mRNA while monocytes and T-cells expressed IL-6 mRNA. IL-1.8 is 
suggested to be one of the principal mediators of bone resorption (12). The patients 
in which on Northern blots an abundant expression of IL-1.8 was demonstrated indeed 
had bone lytic lesions but there were also patients with bone lytic lesions in which we 
could not detect IL-1.8 mRNA (Table 1). This may be due to the limited sensitivity of 
Northern blot analysis or to other bone resorbing factors like TNFa, LT /TNF.B and TGF. 
In addition to the plasma cells, also the majority of the T cells may contribute 
to the elevated IL-1.8 expression in these MM patients. A striking difference was found 
between the T cells in the BM of the healthy control and the T cells in the myeloma BM 
with regard to IL-1.8 expression. About 4 times more T cells contributed to the IL-1.8 
expression in MM BM than in the normal BM. It may be that these T cells are activated 
due to the disease and consequently release a variety of interleukins. In adult T cell 
leukemia (ATL) primary leukemic ATL cells also express IL-1.8 mRNA and this is 
frequently associated with hypercalcemia and thus increased osteolysis (21-22). Our 
findings together with the ATL data suggest a major role for T cells in the production 
of IL-1.8 which could be involved in bone resorption in MM. 
With the ISH technique we could not detect IL-6 mRNA in plasma cells. This 
is in contrast with the findings of Kawano et al. (7) who reported that cultured myeloma 
cells produce IL-6 and express IL-6 receptors on their surface suggesting an autocrine 
growth pattern for myeloma cells. Our findings are in agreement with data from Klein 
et al. who reported that IL-6 was mainly produced by cells of the BM environment and 
not by the myeloma cells (26). We support therefore their suggestion of a paracrine 
rather than an autocrine growth regulation of myeloma cells, in which monocytes and 
T-cells produce IL-6, triggering proliferation of myeloma cells which in turn produce IL-
1.8 causing bone destruction. Because IL-1.8 is also a major promotor of IL-6 
expression in several cell types (2), the production of IL-1.8 by plasma cells, T cells and 
macrophages may be responsible for the induction of IL-6 production in monocytes 
and T cells. This data suggests a "loop" in which malignant plasma cells produce IL-
1.8 which stimulates other cell types to produce IL-6 which in turn stimulates the plasma 
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cells again. 
There are some contradicting reports about factors produced by myeloma 
cells. Most of them concern data obtained from purified cultured myeloma cells 
(6,7, 15). Because it is difficult to obtain highly purified myeloma cells and because 
culturing of cells may induce artefacts the only way to determine the true facts in 
cytokine production is by in vivo studies. By means of the ISH technique we were able 
to detect gene expression directly in the in vivo situation, circumventing purification and 
culturing of BM cells and thus excluding a minor contaminating cell population 
obfuscating the results. ISH for gene expression studies is therefore a powerful tool in 
studying the capacity of the different cell types in the myeloma BM to produce factors 
involved in the pathogenesis of the disease. 
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7. GENERAL DISCUSSION 
This study aims to contribute to the understanding of the underlying mechanism 
that leads to tumor development in MM. Genetic disorders like chromosomal 
translocations, gene amplifications andjor deletions play a fundamental role in 
malignancies, like the t(9;22) in CML and the t(8;14) in Burkitt's lymphoma (see also 
Chapter 1). These genetic disorders can lead to the activation of proto-oncogenes 
which are involved in cell growth control and differentiation. Deregulation of such genes 
can disturb the normal growth pattern of the cell resulting in tumor development. 
Several of such oncogenes have already been identified. Their putative involvement in 
MM tumor cell formation has still to be elucidated. By studying the organization and 
expression of oncogenes in the myeloma cells we tried to determine the difference 
between the malignant cell and its normal counterpart. This should lead to a better 
understanding of tumor aetiology and perhaps to the finding of a tumor specific marker 
for MM. 
7.1. Cytogenetic analysis 
It has been recognized for many years that chromosomal translocations are 
common in tumor cells and that certain aberrations of chromosomes occur repeatedly 
in certain types of tumors (Rowley, 1980; 1982; 1983; Yunis, 1983). Much attention has 
been directed to the issue whether proto-oncogenes known to be residents of 
translocated chromosomes might be positioned close to the breakpoints and whether 
their structure or expression is altered as a consequence of such translocation (see 
also Chapter 1). Also, the appearance of homogeneously staining regions (HSR) or 
double minute chromosomes (DM), which are karyotypical markers of gene 
amplifications (Cowell, 1982), may be indicative for oncogene activation (Aiitalo et 
al., 1983; Schwab et al., 1983). 
The data so far obtained from the cytogenetic analysis of MM BM cells did not 
reveal any aberration that was typically associated with MM (Van den Berghe et al., 
1984; Ferti et al., 1984; DeWald et al., 1985; Philip and Drivsholm, 1976; Liang et al., 
1979; Philip, 1980; Philip et al., 1980; Lewis and MacKenzie, 1984; Chu et al., 1986; 
Ranni et al., 1987). Instead, many abnormalities have been detected, involving several 
chromosomes, but not a single one in every patient. As a consequence no information 
about the primary genetic defect in MM is available from cytogenetic analysis. 
Therefore, other ways of detecting oncogenes in MM had to be explored. 
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7.2. Transfection experiments 
By means of the NIH/3T3 transfection assay we have tried to detect activated 
oncogenes in a mouse model for MM, the 5T model. This assay is based on the 
assumption that neoplastic transformation of the recipient cell is dependent upon the 
acquisition of a mutant allele. This mutant allele is believed to act in a dominant manner 
in both donor and recipients cells. The oncogenic activity of DNA from a wide variety 
of tumor cells has been identified by this assay, frequently employing NIH/3T3 cells 
as acceptor cells (reviewed by Varmus, 1984). Characterization of the transformed 
NIH/3T3 DNA proved that most of the times a mutant member of the ras gene family 
was responsible for the neoplastic transformation (Weinberg, 1984). 
Our data described in Chapter 2 revealed that DNA from various mouse MM 
lines also had the potential to transform NIH/3T3 cells. Further investigations by 
transplanting the transfected cells to athymic nude mice did not lead to the identifica-
tion of a specifically activated oncogene because tumor formation was also observed 
in the negative control, NIH/3T3 cells transfected with NIH/3T3 DNA. It is known from 
the literature that sheared DNA from normal cells can transform NIH/3T3 cells at a low 
frequency (Cooper et al., 1980). So great care must be taken in interpreting the data 
derived from transfection experiments. New approaches to detect mutated ras genes 
in tumor tissue have become available. By the use of specific oligonucleotides it is 
possible to detect a single base pair substitution in the different ras genes of the 
primary tumor (Bas et al., 1987). Single base pair substitution is the mechanism by 
which ras genes are activated (Capon et al., 1983). As a consequence, the use of 
transfection experiments to detect activated ras genes in tumor material has become 
somewhat outdated. However, new oncogenes may still be discovered with this 
technique, especially when other recipient cells are used, more related to the cell type 
of the tumor. 
The suggestion that one or more ras oncogenes may be involved in the 
pathogenesis of MM is supported by three observations. The first one came from 
Tsuchiya et al. (1988) who detected an overexpression of the H-ras gene at the protein 
level in 47% of human MM cases studied. He observed a shorter survival among 
patients with high p21 (ras protein) levels. The second came from Ernst et al. (1988) 
who detected a second transforming gene, N-ras, in a human MM line with a 
rearranged c-myc allele. The third came from Seremetis et al. (1989) who showed that 
introducing H-ras or N-ras oncogenes into immortalized B lymphoblasts could lead to 
malignant transformation and terminal differentiation into plasma cells. These data all 
point to a possible role for activated ras genes in secondary transforming events 
leading to a more malignant stage in the disease. 
7.3. Gene rearrangements and amplifications 
As no typically MM associated chromosomal aberration is known and our 
transfection experiments were not sufficiently successful and informative, we went on 
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searching for oncogenes that were already known to be involved in other B cell 
malignancies. 
A large number of B cell lines of both human and murine origin harbor 
translocations that join the c-myc gene to one of the three lg loci in the manner 
originally predicted by Klein (1981). We have searched for such c-myc rearrangements 
in the 5T MM mouse model and in fresh human MM BM samples (see Chapters 3 and 
4). The Southern blot data revealed that c-myc rearrangement is not a common feature 
in MM. In the mouse model, only one (5T2) of the 8 lines studied showed a c-myc 
rearrangement in BM cells which was also present in ascitic cells (see Chapter 3). 
Another line, 5T14, showed only a c-myc gene rearrangement in the ascitic cells and 
not in the BM. No amplifications were detected. In the human situation, no c-myc gene 
rearrangements were detected in 26 cases studied. Amplification of the c-myc gene 
together with an increased level of expression was found in only 2 out of 24 cases 
(Chapter 4). These data are in agreement with the findings of others. Selvanayagam 
et al. (1988) reported c-myc rearrangements in 2 out of 37 cases of MM. Gazdar et al. 
(1986) reported a c-myc rearrangement in a myeloma cell line. Sumegi et al. (1985) 
detected c-myc rearrangements in plasma cell leukemia, but not in 21 cases of MM. 
It is suggested that altered expression of the c-myc gene, by amplification or 
rearrangement, contributes to the highly malignant nature of plasma cell tumors in the 
leukemic and aggressive phase (Sumegi et al., 1985). Our data are in agreement with 
this hypothesis because: (a) 5T2, the mouse MM line with c-myc rearrangement in the 
BM and ascites, can develop features of a plasma cell leukemia (Ebbeling et al., 1985); 
(b) 5T14 MM showed only a c-myc rearrangement in the ascites cells, and the ascitic 
form is considered to be a more aggressive phase of MM; and (c) the two human 
cases with c-myc amplification both produced ~~;-light chains, a characteristic feature 
of a progressive MM (Durie, 1986). 
We studied also the pvt-like region in MM because of its involvement in variant 
Burkitt's lymphoma and plasmacytoma (see Section 1.3.1. and Chapter 4). Rearrange-
ments of the pvt-region were not detected in the 26 MM cases studied, although there 
is some doubt about one case (nr 8) in which an additional fragment was observed 
in EcoRI digested DNA when the Southern blot was hybridized with a probe situated 
on the 5' site of the pvt-locus. This result could not be confirmed using other restriction 
enzymes, which argues against a major rearrangement event. A possible explanation 
for this result could be the occurrence of a minor mutation in this area, which is only 
reflected in the EcoRI digest. 
Amplification of the pvt-like region was observed in two MM cases (nr 16 and 
nr 25). These cases were the same ones as in which c-myc amplification was found. 
This pvt amplification concerned only the 5' part of the pVk)ike region as it was only 
detected with the most 5' pvt probe and not with pvt probes s'it,uated in the middle and 
at the 3' part of the locus. The c-myc and pvt amplifications were in the same order of 
magnitude. This suggests that c-myc and pvt are situated on the same amplicon. The 
distance between c-myc and pvt is about 300 kb (Mengle-Gaw and Rabbitts, 1987). 
Amplicons of about this size containing c-myc sequences have been detected in a 
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colon carcinoma cell line (COLO 320} and in small cell lung carcinoma cell lines (N417 
and U1285; Kinzler et al., 1986). These amplicons also terminate in the pvt-like region 
(Mengle-Gaw and Rabbits, 1987). The mechanism of these amplifications still has to 
be resolved. 
The amplification of c-myc and pvt was also reflected at the RNA level. A 
transcript from the pvt-like region was detected in the patient with pvt amplification (nr 
25). Only recently it was discovered that the pvt-like region harbored a functional gene. 
Pvt transcripts ranging in size from 1 to 11 kb were detected in the polyadenylated 
RNA fraction of a variety of human cell lines (Shtivelman and Bishop, 1989; Shtivelman 
et al., 1989). The fact that we could detect a transcript of about 7 kb in the total RNA 
fraction from fresh tumor material is likely to be due to the pvt gene amplification. 
Without this amplification expression is probably very low and therefore undetectable 
in the total RNA fraction. 
The biological function of pvt transcripts is still unclear. Likely the pvt-like region 
plays a role in tumorigenesis because of its association with tumor specific abnormali-
ties and involvement in different cell lines. It has been hypothesized that alterations in 
the pvt-locus had an influence on c-myc expression because c-myc was expressed in 
most tumors with structural changes in the pvt-region (Adams et al., 1986). It might be 
that the pvt-region harbors an oncogene of which the normal function is c-myc 
regulation. Another possibility is that the effects of pvt alterations can be transmitted 
to c-myc along the chromosome over a remarkable distance (Adams et al., 1986). The 
discovery of pvt transcripts in tumor cell lines (Shtivelman and Bishop, 1989; 
Shtivelman et al., 1989) and MM tumor material (Chapter 4} makes the first model 
more favorable. 
The c-mycjpvt amplification is a rare phenomenon in MM, just as c-myc 
rearrangement. Therefore it must probably be considered as a late event in carcino-
genesis, perhaps leading to the formation of a more malignant subclone. 
7 .4. Gene over-expression in situ 
In addition to the gene rearrangement and amplification studies to identify 
candidate oncogenes in MM we also wanted to directly measure gene expression in 
tumor cells. Detection of abnormal expression of certain genes is an alternative way 
to get information about candidate oncogenes. Northern blot analysis of total RNA 
isolated from BM cells of MM patients had proven to be a valuable technique in those 
cases in which gene amplification led to abundant expression (see Chapter 4). As the 
number of tumor cells in these BM samples was relatively high, it was possible to 
detect this over-expression. But in most cases the number of tumor cells is relatively 
low in MM BM samples. As a consequence, the transcript of a putative oncogene in 
the tumor cells is considerably diluted by mRNA from normal cells. In that case 
masking the over-expression by Northern blot analysis. Therefore we set up the RNA 
in situ hybridization technique (ISH) to be able to detect mRNA at the single cell level 
(see Chapter 5). By combining this technique with immunofluorescent staining of cell 
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surface markers we were able to detect more precisely the cell type in which the 
mRNA was present. We used HL60 cells with known c-myc amplification and an 
abundant c-myc expression as a model system to set up the technique. We prepared 
biotinylated ssRNA probes to detect the mRNA. ssRNA probes are more sensitive than 
DNA probes and the labeling with biotin makes it possible to use different detection 
methods, e.g. streptavidine or avidine conjugated to different reporter molecules or 
anti-biotin antibodies detectable with fluorochrome- or enzyme-linked second 
antibodies (Bresser and Evinger-Hodges, 1987). By avoiding radioactively labeled 
probes, the ISH technique becomes suitable for routine diagnostics. 
An important step in the ISH assay is the fixation of the cells. The cell surface 
must remain intact and the antigenic determinants have to be preserved. On the other 
hand, the cell surface has to become permeable to let the probe enter the cell. These 
conditions are often contradictory but with the use of the right fixative an appropriate 
result can be obtained. For this purpose we tested several fixatives. In our hands 
paraformaldehyde gave the best results with regard to both cell surface marker 
staining and preservation of the ISH signal. Bresser et al. (1987) favored the 
ethanol/acetic acid fixative, but in our hands this fixative did not give sufficiently 
consistent results. With our modified procedure it was possible to detect c-myc 
expression together with the cell surface marker CD33 in HL60 cells. The detection limit 
was about 30 copies per cell as estimated by dilution experiments (Chapter 5). 
Using this technique we studied IL-1.8 and IL-6 expression in human MM BM 
cells (see Chapter 6). The IL-1.8 gene was depicted because of its involvement in bone 
destruction, a major problem in MM (see Section 1.2.3.). IL-1.8 had been detected in 
myeloma cell cultures (Cozzolino et al., 1989; Kawano et al., 1989) as well as in 
uncultured myeloma BM cells from patients with extensive bone disease (Lichtenstein 
et al., 1989). We wanted to know which cell type was responsible for the production 
of IL-1,8. 
The IL-6 gene was depicted because of the recent observation that myeloma 
cells could produce IL-6 constitutively and expressed the IL-6 receptor (Kawano et al., 
1988). Exogeneous IL-6 stimulated DNA synthesis in some cases suggesting that IL-6 
may function as an autocrine growth factor in MM. If the above statement is correct, 
IL-6 could be a possible oncogene involved in the transformation process in MM just 
as TGF acts as an autocrine growth factor in sarcoma virus-transfected cells (Todaro 
and De Larco, 1978). Also the observation that IL-6 was involved in the generation of 
plasmacytomas in mice made this gene a good candidate for being involved in MM. 
We therefore wanted to know whether the myeloma cells themselves could produce 
IL-6 in the in vivo situation. 
We have studied a few MM BM samples for IL-1.8 and IL-6 expression by ISH. 
The samples were chosen because of their positivity on Northern blot for IL-1.8 and/or 
IL-6 and the availability of sufficient cells. The results described in Chapter 6 indicate 
that in three MM BM samples, positive for IL-1.8 on Northern blot, IL-1.8 mRNA was 
mainly expressed by plasma cells, T cells and macrophages. In one MM BM sample, 
positive for IL-6 on Northern blot, IL-6 mRNA was mainly expressed by T cells and 
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monocytes. We could not detect IL-6 mRNA in the plasma cells of this patient. Two 
other MM patients, of which we didn't have Northern blot data, also showed no ISH 
positivity for IL-6 mRNA in the plasma cells (data not shown). 
These results indicate that myeloma plasma cells can indeed produce IL-1.8 but 
not IL-6. The number of plasma cells expressing the IL-1 mRNA was clearly higher than 
in normal BM. The high number of plasma cells in these BM samples made this cell 
type the major source of IL-1.8. These patients also had lytic bone lesions which is in 
agreement with the assumption that IL-1.8 is the cytokine that causes the bone 
destruction in MM. The fact that we were unable to detect IL-1.8 mRNA by Northern 
blot analysis in every MM patient having lytic bone lesions, argues for the presence of 
another osteoclast activating factor active in these patients. Possible candidates are 
lymphotoxin and tumor necrosis factor which have been shown to be present in some 
MM BM cultures and in the RNA fraction of uncultured MM BM cells (Bertolini et al., 
1986; Garret et al., 1987; Lichtenstein et al., 1989). 
Our data on IL-6 expression are in contrast with the finding of Kawano et al. 
(1988) who reported the expression of IL-6 mRNA by purified cultured myeloma cells 
and by the MM cell line U266. But Klein et al. (1989} reported that they could not 
detect IL-6 mRNA in myeloma cells and the U266 cell line. We also tested this cell line 
and also were unable to detect IL-6 mRNA in U266. Klein et al. detected only IL-6 
mRNA in the adherent cell fraction of the BM cells. These adherent cells are likely to 
represent the monocytes which have been shown positive for IL-6 by our ISH 
technique. An explanation for the presence of IL-6 in the myeloma cell cultures of 
Kawano et al. (1988) could be a contamination with monocytes in the purified myeloma 
cell fraction. They claim that their myeloma cell fractions are more than 95% pure. 
However, only a few monocytes are needed to explain the observed IL-6 positivity 
(Helle et al., 1988). 
Although the number of MM cases examined in Chapter 6 is too limited to allow 
firm conclusions, these results together with the results of Klein et al. (1989) are more 
indicative for a paracrine growth control of IL-6 in MM than an autocrine one. This 
conclusion is supported by the observation that transgenic mice which had received 
the IL-6 gene fused with a human lgH-enhancer, did not generate plasma cell 
neoplasia (Suematsu et al., 1989). These mice showed a polyclonal increase of lgG1 
in the blood and a massive plasmacytosis. The plasma cells were not transpantable 
to syngeneic mice and did not have chromosomal aberrations like c-myc rearrange-
ments. Thus, deregulated IL-6 gene expression alone is not sufficient to induce 
plasmacytoma. 
It is suggested that additional genetic changes are required for the generation 
of plasma cell neoplasia. IL-6 can be a major factor involved in this oncogenic 
transformation by the fact that it can trigger plasma cell proliferation. These proliferating 
plasma cells may be more susceptible for malignant conversion by additional genetic 
changes. This situation resembles the situation in transgenic mice which had received 
the c-myc oncogene. These mice also show excessive benign proliferation, not of 
plasma cells but of B-cells. After variable latency periods most of these mice developed 
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8-cell malignancies suggesting the occurrence of a second transforming event in this 
expanded 8-cell population (Harris et al., 1988). 
In the case of MM IL-1 and IL-6 can act synergystically in myeloma cell 
proliferation. IL-1.8, produced by the MM plasma cells, could induce IL-6 production in 
monocytes and the stromal cells of the 8M (Van Damme et al., 1987; Nemunaitis et 
al., 1989). This IL-6 could bind to the IL-6 receptor on the MM plasma cells, triggering 
their proliferation, giving rise to more plasma cells, which in turn produce more IL-1.8 
causing bone destruction and inducing IL-6 production by monocytes etc. (see Fig. 1). 
These proliferating plasma cells could then undergo secondary transforming events 
leading to a more malignant stage of the disease. The fact that in some cases of MM 
the response to IL-6 decreases (Asaoku et al., 1988), is in agreement with this 
phenomenon and with the general hypothesis that during progression of the disease 
dependence on growth factor(s) decreases (Weinberg, 1985). 
IL-6 
BM stroma-cells 
~
~~ 
induction 
of IL-6 
------.. IL-1+ ~-----------1~1 bone-destruction 
IL-6 
induction 
of IL-6 
monocyte 
Figure 1. A possible mechanism for stimulation of plasma cell proliferation and bone destruction in 
MM. 
Other cell types and cytokines may also be involved in this proliferation model 
for MM, like T cells and macrophages, IL-5 and IL-3. This model may be adequate for 
some cases of MM but an alternative model should be proposed for the cases in 
which we did not detect IL-1.8 or IL-6 gene expression. However, lack of IL-1.8 and IL-
6 expression might also be due to the detection limit of the Northern blot assay. 
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Therefore the ISH studies should be expanded to other cytokines, more phenotypic 
markers and more MM BM samples to unravel the true growth factor network in MM. 
Understanding the requirements for growth factors in MM should lead to a more 
successful intervention therapy. In the laboratory it will simultaneously facilitate the 
production of MM cell lines, which will stimulate studies of the biology of MM. This may 
lead to more adequate karyotypic analysis of MM and thereby to the discovery of a 
tumor specific marker for MM. 
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SUMMARY 
Multiple myeloma (MM) is a malignant proliferating disorder of the B lymphocyte 
lineage, characterized by an increasing proportion of plasma cells in the bone marrow, 
a high and progressively increasing concentration of a homogeneous immunoglobulin 
in the blood and the occurrence of osteolytic bone lesions. It is predominantly a 
disease of the elderly. The incidence of MM in the Netherlands is approximately 3 in 
100,000 inhabitants. The prognosis for survival is about 3 years. 
In this thesis a study was made of genetic defects responsible for the 
transforming event in MM. The purpose of this study was to increase our insight into 
the underlying mechanism of tumor formation and to find tumor specific markers that 
would improve the diagnosis MM in an early stage of the disease. 
Since the discovery of oncogenes in the early eighties, much progress has been 
made in understanding tumor development. Oncogenes can play an important role in 
the process of malignant transformation. Oncogenes are activated proto-oncogenes, 
which in normal cells regulate growth and differentiation. Alterations in such genes by 
translocations, amplifications, point-mutations or deletions can disturb the normal 
growth pattern of the cell leading to malignant conversion. 
An approach to detect oncogenes in tumor material is the use of the NIH/3T3 
transfection assay. This assay is based on the neoplastic transformation of murine 
NIH/3T3 recipient cells upon acquisition of an oncogene. DNA derived from three in 
vivo propagated murine MM lines (5T2, 5T7 and 5T14) was transfected into NIH/3T3 
cells (Chapter 2). After isolation and injection of the transfected cells into nude mice, 
tumor development was observed in all three cases studied. Secondary transfection 
rounds were performed with DNA derived from these tumors, ligated to a dominant 
selective marker in order to distinguish between tumor DNA and NIH/3T3 DNA. Tumor 
development was again seen in all cases but also in the negative control, which 
hampered the isolation of the transforming gene from the murine MM lines. 
Further investigations of oncogenes that might be involved in M M were focussed 
on oncogenes known to be involved in other B-cell neoplasia. C-myc, for example, is 
involved in Burkitt's lymphoma and mouse plasmacytoma. It is activated by a 
translocation event in which one of the three immunoglobulin loci are involved. The 
presence of such rearrangements of c-myc was investigated in eight murine MM lines 
and 21 human MM patients (Chapters 3 and 4). Southern blot data from DNA derived 
from MM bone marrow cells revealed that c-myc rearrangement is not a common 
phenomenon in MM. Rearrangements were only observed in the bone marrow and 
ascites cells of the 5T2 MM and in the ascites cells of the 5T14 MM. Amplification of 
c-myc, as is often observed in plasma cell leukemias, was only detected in two out of 
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21 human MM cases. This amplification was also reflected at the RNA level. Northern 
blot data revealed an abundant expression of c-myc mRNA in one MM patient with 
c-myc amplification. The pvt-region, often involved in translocations in variant Burkitt's 
lymphoma and plasmacytoma, was also studied in human MM. No clear rearrange-
ments were detected but amplification of the pvt locus was found in the same two 
patients that also showed c-myc amplification. This amplification concerned only the 
5' part of the locus. The amplification was in the same order of magnitude for both 
c-myc and pvt, which argues for the presence of c-myc and pvt on the same amp Iicon. 
The distance between c-myc and pvt on chromosome 8 is about 300 kb. Amplicons 
of that size containing myc sequences and ending within the pvt-region have been 
shown to be present in other tumors as well. The pvt gene amplification in MM also led 
to an abundant expression of a transcript of about 7 kb. So far, pvt-transcripts (ranging 
from 1-11 kb) had only been described in some tumor cell lines. Thus, detection of a 
pvt transcript in de total RNA fraction from fresh tumor material is exceptional. 
The biological function of the pvt transcript is yet unclear. It is suggested that 
pvt may be involved in c-myc regulation. Because c-myc and pvt amplifications were 
detected in two MM patients that produced only K:-light chains, a characteristic feature 
of a progressive stage of the disease, it was presumed that c-myc and pvt were only 
activated in a late stage of the disease. This presumption was confirmed by the fact 
that in the mouse model for MM c-myc rearrangements were only detected in the 5T2 
MM line that can develop features of a plasma cell leukemia and in the ascites of 5T14 
MM, a more aggressive phase of MM. This activation of c-myc and pvt is probably the 
course of the development of a more malignant cell variant. 
To get more information about aberrant expression of certain genes in MM, we 
set up the RNA in situ hybridization (ISH) technique combined with immunofluorescent 
staining of cell surface markers. With this technique it is possible to detect a specific 
mRNA in the cytoplasm of a single cell. Cell morphology was sufficiently preserved, as 
were antigenic determinants. By double staining of antigens on the cell surface and 
mRNA in the cytoplasm of the cells it was possible to determine more precisely the 
cell type in which the mRNA is expressed (Chapter 5). This information about gene 
expression in a well defined cell type cannot be achieved by conventional methods like 
the Northern blot assay. ISH is a useful technique, especially for the study on MM, 
because the proportion of malignant plasma cells in the MM bone marrow is in an early 
phase of the disease relatively low, which makes it difficult to answer questions on 
gene expression in these cells. 
Using the ISH technique we have studied the expression of IL-1B and IL-6 in 17 
MM bone marrow samples (Chapter 6). IL-1B was choosen because of its osteoclast 
activating activity which leads to bone destruction, an important feature of MM. IL-6 
was choosen because of its growth factor activity on plasma cells. From in vitro studies 
it was postulated that IL-6 could act as an autocrine growth factor in MM, making it a 
candidate oncogene involved in the transformation process. We tested this hypothesis 
in a few human MM by the ISH technique. Biotinylated ssRNA probes specific for IL-6 
and IL-1 B were generated and used in the ISH assay together with cell surface marker 
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staining to distinguish plasma cells from other cell types. These experiments showed 
that malignant plasma cells were the major cell type in the MM bone marrow that 
expressed IL-1B. This is indicative for the important role of the malignant plasma cell 
clone itself in the characteristic bone destruction. IL-6 expression, on the other hand, 
could not be detected in the plasma cells. Monocytes were the major population 
expressing this gene. This finding argues against an autocrine growth factor activity of 
IL-6 in MM. Instead, IL-6 is more likely acting as a paracrine growth factor for MM 
plasma cells. 
IL-1,8 and IL-6 may act synergystically on plasma cell proliferation. A model has 
been postulated in which plasma cells can produce IL-1, which induces IL-6 production 
in monocytes and stromal cells in the bone marrow. This IL-6 stimulates the plasma 
cell to proliferate, giving rise to more cells producing more IL-1,8. This IL-1,8 again can 
cause plasma cell proliferation through IL-6 induction and bone-destruction. Because 
MM is a heterogeneous disease, this model is probably not true for every case. 
Extension of the ISH studies with other cytokine specific probes on more MM samples 
is needed to unravel the cytokine network in MM. 
The studies described in this thesis did not lead to the discovery of the primary 
genetic defect responsible for the onset of MM, but have contributed to the identifica-
tion of genes possibly involved in a more advanced stage of the disease and to the 
understanding of the role of IL-1,8 and IL-6 in MM. 
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SAMENVATTING 
Het multipel myeloom (MM) is een kwaadaardige aandoening uitgaande van 
cellen van de B lymfocyten reeks. Deze ziekte wordt gekenmerkt door de aan-
wezigheid van een toenemend percentage plasmacellen in het beenmerg, een hoog 
en progressief toenemend gehalte aan een homogeen immunoglobuline in het bloed, 
en botlesies. MM komt voornamelijk voor bij oudere mensen en de incidentie in 
Nederland is ongeveer 3 per 100.000 inwoners. De prognose is slechts 3 jaar. 
Dit proefschrift beschrijft onderzoek naar de genetische defecten die verant-
woordelijk zijn voor de transformerende gebeurtenis in MM. Het doel van het 
onderzoek was om een beter inzicht te krijgen in het mechanisme dat ten grondslag 
ligt aan de tumorvorming en het opsporen van tumor specifieke markers waarmee de 
diagnose van MM in een vroeg stadium verbeterd zou kunnen worden. 
De ontdekking van oncogenen in het begin van de jaren tachtig heeft geleid tot 
een grate vooruitgang in ons begrip van tumorontwikkeling. Oncogenen spelen een 
belangrijke rol in de transformatie van een normale eel tot een tumorcel. Oncogenen 
zijn geaktiveerde proto-oncogenen die normaal een funktie vervullen in de regulatie van 
celgroei en -differentiatie. Veranderingen in zulke regulatie-genen, bijvoorbeeld door 
translocaties, punt-mutaties, amplificaties enjof deleties, kunnen aanleiding geven tot 
een verstoring van het normale groeipatroon van de eel, waardoor kanker kan 
ontstaan. 
Een manier om oncogenen op te sporen is de NIH/3T3 transformatietest. Deze 
test is gebaseerd op de neoplastische transformatie van muize NIH/3T3 ontvangercel-
len door de opname van een oncogen. Door ons werd DNA van drie getransplan-
teerde muize MM lijnen (5T2, 5T7 en 5T14) getransfekteerd naar NIH/3T3 cellen 
(Hoofdstuk 2). Na isolatie en injectie van deze getransformeerde cellen in naakte 
muizen worden er tumoren gevonden in aile drie gevallen. Met het DNA afkomstig van 
deze tumoren werd een tweede transfektieronde uitgevoerd. Om onderscheid te 
kunnen maken tussen het tumor DNA en het NIH/3T3 DNA werd het tumor DNA 
geligeerd aan een dominante selektieve marker. Oak deze laatste getransfekteerde 
cellen veroorzaa~ten tumoren in naakte muizen. Echter, oak de negatieve controle, 
NIH/3T3 DNA geligeerd aan de selektieve marker, gaf aanleiding tot tumorontwikke-
ling. Dit verhinderde de isolatie van eventueel transformerende genen uit de muize MM 
lijnen. 
Verder onderzoek naar de rol van oncogenen in MM werd gericht op 
oncogenen waarvan bekend was dat zij betrokken waren bij andere B eel neoplasieen, 
zoals c-myc, betrokken bij het Burkitt's lymfoom en het plasmacytoom. Dit gen wordt 
geaktiveerd door een translokatie waarbij een van de drie immunoglobuline loci 
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betrokken is. De aanwezigheid van eventuele herschikkingen van c-myc werd 
bestudeerd in acht muize MM lijnen en in 21 MM patienten (Hoofdstuk 3 en 4). De 
resultaten van Southern blot analyse van DNA van beenmergcellen toonden aan dat 
c-myc herschikking niet een algemeen verschijnsel is in MM. Herschikking werd aileen 
gevonden in beenmerg en ascites cellen van 5T2 en in ascites cellen van 5T14. 
Amplificatie van c-myc, dat vaak gevonden wordt in plasmacelleukemieen, kon slechts 
in twee gevallen van MM worden gedetecteerd. 
De pvt-regio, een sequentie die vaak betrokken is bij het variant Burkitt's 
lymfoom, werd ook onderzocht in MM (Hoofdstuk 4). Er werden geen duidelijke 
herschikkingen gevonden maar wei een amplificatie van het 5' gedeelte van deze regia 
in dezelfde twee patienten waarin ook een c-myc amplificatie was gevonden. De mate 
van amplificatie was gelijk voor zowel c-myc als pvt. Dit is een aanwijzing voor de 
aanwezigheid van c-myc en pvt op hetzelfde amp Iicon. De afstand tussen c-myc en pvt 
op chromosoom 8 bedraagt ongeveer 300 kb. Amplicons van die grootte die c-myc 
sequenties bevatten en in de pvt-regio eindigen werden reeds gevonden in andere 
tumoren. Deze pvt amplificatie gaf ook aanleiding tot een verhoogde expressie van een 
pvt transcript van ongeveer 7 kb. Pvt transcripten, varierend in grootte van 1-11 kb, 
werden reeds eerder in enkele tumor cellijnen gevonden. De detectie van een pvt 
transcript in de totale RNA fraktie van vers tumor materiaal is dus uitzonderlijk. De 
biologische betekenis van dit pvt transcript is nog niet duidelijk. Er is wei gesuggereerd 
dat pvt betrokken zou zijn bij de regulatie van c-myc. 
Het feit dat c-myc en pvt amplificaties slechts werden gevonden in twee MM 
patienten die beiden aileen ~~:-Iichte ketens produceerden, een karakteristiek kenmerk 
voor een progressief stadium van de ziekte, doet vermoeden dat c-myc en pvt slechts 
geaktiveerd worden in een late fase van de ziekte. Dit vermoeden werd bevestigd in 
het muizemodel voor MM, waar c-myc veranderingen aileen werden gevonden in de 
5T2 lijn die zich kan ontwikkelen tot een plasmacelleukemie en in de ascites vorm van 
5T14, een agressieve vorm van MM. De aktivering van c-myc en pvt zou aanleiding 
kunnen geven tot de ontwikkeling van een meer maligne celvariant van de tumor. 
Om meer informatie te verkrijgen over eventueel veranderde genexpressie in 
het MM hebben we de in situ hybridisatie (ISH) techniek opgezet, gecombineerd met 
een immunofluorescentie kleuring van celoppervlakte antigenen. Met deze techniek 
is het mogelijk om specifiek mRNA te detekteren op "single cell" niveau. De celmorfolo-
gie en antigene determinanten bleken daarbij in voldoende mate behouden te kunnen 
worden. Door dubbelkleuring van antigenen op het celoppervlak en mRNA in het 
cytoplasma van de eel kon het celtype worden bepaald waarin het mRNA aanwezig 
was (Hoofdstuk 5). Zulke informatie kan niet verkregen worden m.b.v. conventionele 
methoden zoals de Northern blot assay. De ISH techniek is een waardevolle techniek, 
speciaal voor het bestuderen van RNA expressie in MM, omdat in een vroeg stadium 
van de ziekte het aantal maligne plasmacellen in de beenmerg aspiraten relatief laag 
is, waardoor het moeilijk is om een uitspraak te doen over de genexpressie specifiek 
in deze cellen. 
Met behulp van de ISH techniek hebben we de expressie bestudeerd van IL-1.8 
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en IL-6 in zeventien MM beenmerg monsters (Hoofdstuk 6). IL-1,8 was uitgekozen 
vanwege zijn osteoclast activerend vermogen, welke aanleiding kan geven tot 
botafbraak, een belangrijk kenmerk van MM. IL-6 was uitgekozen vanwege zijn 
groeifaktor activiteit voor plasmacellen. Op basis van in vitro onderzoek is door 
anderen gepostuleerd dat IL-6 een autocrine groeifaktor is voor MM, dus een kandi-
daat-oncogen in de transformatie bij MM. We hebben deze hypothese getoetst in de 
in vivo situatie door gebruik te maken van de ISH techniek. Specifieke, gebiotinyleerde 
ssRNA probes voor IL-6 en IL-1,8 warden gemaakt. Deze warden gebruikt voor ISH in 
combinatie met verschillende oppervlakte markers om de plasmacellen te kunnen 
onderscheiden van andere celtypen. Uit de ISH experimenten bleek dat in beenmerg 
van een MM patient, de maligne plasmacel het belangrijkste celtype was waarin IL-1,8 
expressie aangetoond kon worden. Dit is een indikatie voor de belangrijke rol die de 
maligne plasmacel kan vervullen in de botafbraak. IL-6 daarentegen, kon niet worden 
aangetoond in de plasmacellen. Het bleek dat de monocyten de belangrijkste 
celpopulatie vormden die IL-6 tot expressie bracht. Deze bevindingen zijn in 
tegenspraak met de vermeende autocriene groeifaktor aktiviteit van IL-6 in MM. IL-6 
lijkt meer een paracriene groeifaktor te zijn in MM. 
IL-1,8 en IL-6 zouden synergistisch kunnen werken in de stimulering van de 
plasmacel proliferatie. Plasmacellen produceren IL-1,8 dat de IL-6 productie in 
monocyten en stromale cellen van het beenmerg kan induceren. Dit IL-6 kan op zijn 
beurt de plasmacel proliferatie stimuleren, waardoor er meer plasmacellen ontstaan die 
IL-1,8 produceren. Dit IL-1,8 kan weer plasmacel proliferatie induceren via IL-6 en 
botdestruktie veroorzaken. Omdat MM een zeer heterogeen ziektebeeld is, gaat dit 
model waarschijnlijk niet op voor elk geval van MM. Een uitbreiding van de ISH studies 
met andere cytokine probes bij een grater aantal gevallen van MM zal nodig zijn om 
het cytokine netwerk in MM te ontrafelen. 
De studies die in dit proefschrift beschreven zijn, hebben niet geleid tot de 
opheldering van het primaire genetische defekt dat verantwoordelijk is voor het 
ontstaan van MM, maar hebben wei bijgedragen tot de identifikatie van genen die 
mogelijk betrokken zijn in een meer gevorderd stadium van de ziekte, en tot een beter 
begrip van de rol van IL-1,8 en IL-6 in MM. 
92 
AP 
ATL 
BCGF 
B-CLL 
BM 
BMG 
BrdU 
BSA 
BSF 
c 
CAB-NHS 
eDNA 
CML-BC 
c-one 
cpm 
D 
DM 
DMSO 
DNA 
EBV 
EGF 
FAGS 
FCS 
FITC 
GAPDH 
GTP 
HGF 
HSR 
IFN 
lgH 
lgl 
IL 
ISCN 
ISH 
JH 
kb 
ABBREVIATIONS 
alkaline phosphatase 
adult T-cell leukemia 
B-cell growth factor 
B-cell chronic lymphocytic leukemia 
bone marrow 
benign monoclonal gammapathy 
5-bromo-2-deoxyuridine 
bovine serum albumin 
B cell stimulatory factor 
constant immunoglobulin gene segment 
E-caproylamidobiotin-N-hydroxysuccinimide ester 
complementary deoxyribonucleic acid 
chronic myeloid leukemia with lymphoblastic blast crisis 
cellular oncogene 
counts per minute 
immunoglobulin diversity gene segment 
double minute 
dimethyl sulfoxide 
deoxyribonucleic acid 
Epstein Barr virus 
epidermal growth factor 
fluorescent activated cell sorter 
fetal calf serum 
fluorescein isothiocyanate 
glyceraldehyde-3-phosphate dehydrogenase 
guanosine 5'-triphosphate 
hepatocyte growth factor 
homogeneously staining region 
interferon 
immunoglobulin heavy chain 
immunoglobulin light chain 
interleukin 
international system for human cytogenetic nomenclature 
in situ hybridization 
joining region of the heavy chain locus 
kilo base 
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LT 
MG 
MM 
MNC 
MoAb 
MPC 
mRNA 
MW 
near 
OAF 
r2P)a-dCTP 
PB 
PBS 
PCL 
PF 
pvt 
RIC 
RNA 
SA 
SDS 
ss 
sse 
t 
T-ALL 
TGF 
TNF 
tRNA 
TRITC 
v 
v-ane 
94 
lymphotoxin 
monoclonal gammapathy 
multiple myeloma 
mononuclear cells 
monoclonal antibody 
mouse plasmacytoma 
messenger ribonucleic acid 
molecular weight 
neomycine resistant 
osteoclast activating factor 
32p labeled deoxycytidine triphosphate 
peripheral blood 
phosphate buffered saline 
plasma cell leukemia 
paraformaldehyde 
plasmacytoma variant translocation 
rat immunocytoma 
ribonucleic acid 
streptavidin 
sodium dodecyl sulphate 
single stranded 
standard saline citrate 
translocation 
T cell acute leukemia 
transforming growth factor 
tumor necrosis factor 
transfer ribonucleic acid 
tetramethyl rhodamine isothiocyanate 
variable immunoglobulin gene segment 
viral oncogene 
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